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Abstract 
Neuropathic pain is defined as “pain initiated or caused by a primary lesion or dysfunction 
in the nervous system”. In contrast to physiological pain that warns of noxious stimuli likely 
to result in tissue damage, neuropathic pain serves no protective function. Examples of 
neuropathic pain states include postherpetic neuralgia (shingles) and phantom limb / stump 
pain. This pain state also exists in the orofacial region, with the possibility of several 
variants including atypical odontalgia and burning mouth syndrome. There is a paucity of 
information on the prevalence of neuropathic pain in the orofacial region. One study 
assessed patients following endodontic treatment and found that approximately 3 to 6% of 
patients reported persistent pain. Patients predisposed to the condition atypical odontalgia 
(phantom tooth pain) include those suffering from recurrent cluster or migraine headaches.  
 
Biochemical and neurobiological processes leading to a neuropathic pain state are complex 
and involve peripheral sensitisation, and neuronal plasticity of the central and peripheral 
nervous systems. Subsequent associated pathophysiology includes regional muscle spasm, 
sympathetic hyperfunction, and centralisation of pain. The relevant clinical features of 
neuropathic pain are: (i) precipitating factors such as trauma or disease (infection), (ii) pain 
that is frequently described as having burning, paroxysmal, and lancinating or sharp 
qualities, and (iii) physical examination may indicate hyperalgesia, allodynia and 
sympathetic hyperfunction. The typical patient complains of persistent, severe pain, yet 
there are no clearly identifiable clinical or radiographic abnormalities. Often, due to the 
chronicity of the problem, afflicted patients exhibit significant distress and are poor pain 
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historians, thus complicating the clinician’s task of obtaining a detailed and relevant clinical 
and psychosocial history.  
 
An appropriate analgetic blockade test for intraoral sites of neuropathic pain is mucosal 
application of topical anaesthetics. Other, more specific, tests include placebo controlled 
lignocaine infusions for assessing neuropathic pain, and placebo controlled phentolamine 
infusions for sympathetically maintained pain. The treatment and management of 
neuropathic pain is multidisciplinary. Medication rationalisation utilises first-line 
antineuropathic drugs including tricyclic antidepressants, and possibly an anticonvulsant. 
Topical applications of capsaicin to the gingivae and oral mucosa are a simple and effective 
treatment. Neuropathic pain responds poorly to opioid medication. Psychological 
assessment is often crucial in developing strategies for pain management. Psychological 
variables include distress, depression, expectations of treatment, motivation to improve, 
and background environmental factors.   
 
To enable a greater understanding of neuropathic pain, thereby leading to improved 
treatments, high-performance liquid chromatography-mass spectrometry is one analytical 
technique that has the potential to contribute to our knowledge base. This technique allows 
drugs and endogenous substances to be assayed from one sample in a relatively short time. 
The technique can identify, confirm, and measure the concentrations of multiple analytes 
from a single sample. 
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Glossary of Terms* 
 
 
after discharge continued firing of dorsal horn neurons following 
repetitive peripheral stimulation 
 
algesic pain producing 
 
algogen pain producing substance 
 
algogenic pain producing 
 
allodynia pain from stimulus that does not normally cause pain 
 
analgetic pain relieving, analgesic 
 
atypical facial pain**  a diagnosis characterised by vague signs and symptoms 
with significant psychological factors 
 
atypical odontalgia severe, throbbing pain without major pathology, 
phantom tooth pain 
 
central sensitisation a phenomenon occurring in the dorsal horn and other 
central structures causing allodynia and secondary 
hyperalgesia in uninjured tissue surrounding a site of 
injury 
 
complex regional pain 
syndrome (CRPS) type I 
a syndrome that usually develops after an initiating 
noxious event, is not limited to the distribution of a 
single peripheral nerve, and is apparently 
disproportionate to the inciting event 
 
complex regional pain 
syndrome type II 
burning pain, allodynia and hyperpathia usually in the 
hand or foot, after partial injury to a nerve or one of its 
major branches 
 
homeopathy (US) / 
homoeopathy (UK) 
 
a traditional system of diagnosing and treating ailments 
hyperalgesia increased response to a painful stimulus 
 
                     
*  Definitions from the International Association for the Study of Pain (IASP), 1994. 
** Definition from the IASP, 1986. Term discontinued in 1994. 
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neuropraxis crush injury to a nerve 
 
neurotmesis sectioning or cutting of a nerve 
 
nociception activation of peripheral nociceptor which is recognised 
centrally as pain 
 
peripheral sensitisation a phenomenon where inflammatory mediators sensitise 
high threshold nociceptors 
 
physiological pain pain that serves a protective function (as a warning for 
tissue damage), is transient and well localised 
 
sympathetic hyperfunction characterised by changes in skin temperature, blood 
flow, resting sweat output and presence of oedema 
 
sympathetically maintained 
pain 
defined as pain that is maintained by sympathetic 
efferent innervation or circulating catecholamines 
 
windup progressive increase in response of dorsal horn neurons 
due to repetitive peripheral stimulation 
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CHAPTER 1 
Introduction 
The physiological purpose of pain is to serve as a warning of actual or potential tissue 
damage and, consequently, to arouse the organism and initiate withdrawal reflexes to 
prevent any further tissue damage. The release of putative inflammatory mediators from 
tissue damage initiates the expression of substances such as nerve growth factor that may 
cause maladaptive changes such as neuronal sprouting that, in turn, may lead to 
neuropathic pain. Neuropathic pain is defined as “pain initiated or caused by a primary 
lesion or dysfunction in the nervous system” by the International Association for the Study 
of Pain (IASP) (1).  
 
Causal factors in the development of neuropathic pain include injury, infection and surgery. 
The emergence of neuropathic pain following dental or maxillofacial injury or surgery / 
treatment presents an unexpected challenge to the clinician and the patient as it is unlikely 
to be cured or resolved in the postoperative surgical phase. The expectations of the 
clinician and patient that a chronic pain condition may develop as a result of injury or 
surgery can vary depending on the site and severity of injury - for example, patients with 
back pain are often familiar with the fact that persistent pain and disability may result from a 
severe back injury. In addition, orthopaedic surgeons are likely to provide sufficient 
information to the patient concerning the risks and limitations of surgery to cure or alleviate 
back pain. In contrast, in the area of dental, oral and maxillofacial surgery, patients are 
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usually well informed about likely functional and aesthetic limitations from treatments (e.g. 
surgery, implants and reconstruction), but from both the patient’s and the clinician’s 
viewpoint, chronic pain is an unexpected complication of dental treatment. Consequently, 
the clinician is left to deal with a patient who has a complication that is complex and 
multidimensional involving sensory (pathophysiological) and affective (psychological) 
aspects. Dental or surgical revision for neuropathic pain, unfortunately, is usually 
contraindicated as there is a high risk of propagating further maladaptive changes in the 
sensory pathways of the peripheral and central nervous systems.  
 
Neuropathic pain of the oral mucosa and gingivae, and spreading to the face, following 
dental treatment (usually a dental extraction) has been termed “atypical odontalgia”. It has 
been defined as a “severe throbbing pain in the tooth without major pathology” (1). 
Documentation of the condition in the dental literature is scarce and accordingly, there is a 
paucity of information regarding diagnostic and treatment / management procedures. 
Neuropathic orofacial pain was first described as a painful and unusual condition that 
occurs in the dentoalveolar structures and oral mucosa (2). Patients reported pain that was 
moderate to severe in intensity, and with a pattern of referral that may cross the anatomical 
midline (of the mandible and maxilla) and possibly involve the face. Pain can occur in single 
or multiple sites (mucosa, extraction sites and remaining teeth). It has also been described 
as phantom tooth pain due to insufficient information  for providing a physiological 
explanation, and its clinical similarity with phantom limb pain (3, 4). The lack of clinical and 
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radiographic evidence to establish a diagnosis pertaining to organic pathology gave 
credence to early investigators that there was a psychogenic basis to the condition (2). 
 
There have been relatively few studies investigating the condition and there is a combined 
total of less than 200 patients reported in the literature (2, 5, 6, 7, 8). Most of the 
published reports are epidemiological and there is remarkably little information available for 
clinicians with respect to diagnostic tests and treatment / management strategies. The 
aetiology of neuropathic orofacial pain remains poorly understood but the limited data 
available show that endodontic procedures may account for up to 50% of the cases (9).  
   
The patient afflicted with neuropathic oral / orofacial pain may present to the clinician with 
a persistent, severe pain without clearly identifiable clinical or radiographic abnormalities. 
Accordingly, further investigative and curative surgical procedures may be instigated in an 
attempt to remove the likely anatomical source of the pain. However, the resolution of 
neuropathic pain does not rely upon surgical intervention but on appropriate pain 
management strategies. Indeed, where multiple surgical interventions are carried out, the 
likely outcome is a worsening of the condition. In addition to the clinical challenge of 
diagnosis and management, the lack of pain relief from previous procedures may cause 
some patients to display openly negative emotions such as frustration, anger, mistrust and 
hostility toward clinicians. This is based on patient psychological factors such as their 
expectations and assurances of cure (pain relief) from surgical intervention. As a 
consequence of the chronicity of the complaint and the high levels of pain associated with 
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the condition, there is the possibility of psychological morbidity, and unfortunately, the real 
potential of suicide in some patients.  
 
A recent review of psychological factors in patients with pain identified a number of crucial 
points (10): 
(i) expectations of surgery to ‘fix’ the pain, when there is significant 
background psychological distress, often lead to poor outcomes (11), 
(ii) accurate and comprehensible information provided by the surgeon to the 
patient preoperatively may change the way the patient construes his / her pain, and 
may reduce the risk of the patient developing postoperative chronic pain (12), 
(iii) absence of information, on the other hand, may promote anxiety and fear in 
the presence of pain (13), and lead to avoidance of normal daily activities (14), 
(iv) failure to attend to the patient’s fear of pain may interfere with patient’s 
trust of the surgeon and, by a conditioning process, make more likely the rejection 
of any future surgeon’s advice (15, 16).   
In the study by Vickers and Harris (10) they concluded that it is essential that the clinician 
(surgeon) integrates physiological and psychological factors in the pre-, peri- and 
postoperative phases in order to reduce the potential risks to both the patient and the 
surgeon. 
  17
Historical perspectives  
Marbach, Hulbrock, Hohn and Segal (17) suggested that John Hunter, over 200 years 
ago, was the first to describe neuropathic orofacial pain : 
 
There is one disease of the jaws which seems in reality to have no connection to the 
teeth, but of which the teeth are generally suspected to be the cause. This deserves to 
be taken notice of in this place, because operators have frequently been deceived by 
it, and even sound teeth have sometimes been extracted through an unfortunate 
mistake. 
 
This pain is seated in some part of the jaws. As simple pain demonstrates noting, a 
tooth is often suspected, and is perhaps drawn out; but still the pain continues, with 
this difference, however, that it now seems to be the root of the next tooth; it is then 
supposed by either the patient or the operator, that the wrong tooth was extracted; 
wherefore, that in which the pain now seems to be is drawn, but with as little benefit. 
I have known cases of this kind, where all the teeth of the affected side of the jaw 
have been drawn out, and the pain continued in the jaw; in others, it has had a 
different effect, the sensation of pain has become more diffused, and has at last, 
attacked the corresponding side of the tongue. In the first case, I have known it 
recommended to cut down upon the jaw, and even to perforate and cauterize it, but 
all without effect. I have seen cases of some years standing, where the hemlock has 
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succeeded when the bark has had no effect; but sometimes all attempts prove 
unsuccessful.  
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Hemlock and Peruvian Bark, used to treat ‘toothache’ by Hunter, are still in current use by 
medical herbalists and homoeopathic practitioners. Hemlock (Conium maculatum) is the 
herb that supposedly caused the death of Socrates by poisoning and is used as a sedative 
(18), while in the homoeopathic literature it has been used to treat toothache (19). Peruvian 
Bark (Cinchona officinalis) has been used as an antineuralgic remedy in herbal 
preparations (18). Interestingly, a recent finding in a reprint of an old homoeopathic text 
first published in 1885 describes the use of capsicum to treat “burning and throbbing pains 
of the gums” (20). The therapeutic use of capsaicin, the active agent of capsicum, to treat 
neuropathic pain, a condition that has predominantly burning and throbbing pain qualities, is 
discussed in a later section of this thesis.  
 
Aims of this treatise 
Neuropathic pain has only recently been recognised by dental and medical practitioners as 
a pain state that deserves urgent understanding. Because of this recent awareness, its 
epidemiology and pathophysiology are undergoing extensive research in order that 
preventive measures and effective clinical treatments can become possible. While the 
majority of this research is directed toward neuropathic pain states associated with medical 
conditions, there is now a growing recognition in the dental field of the need to investigate 
orofacial presentations of neuropathic pain. The purpose of this treatise is to review the 
state of current knowledge of neuropathic orofacial pain and to present appropriate 
guidelines in its diagnosis and treatment. Accordingly, in this thesis the areas reviewed 
include the epidemiology, pathophysiology, clinical features, appropriate diagnostic tests, 
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and pharmacological and psychological strategies of management for neuropathic orofacial 
pain. A further aim of this thesis is to conduct a preliminary research study using high-
performance liquid chromatography-mass spectrometry in order to develop an assay 
technique (using standards of drug and endogenous substances) that would provide further 
information toward the understanding, diagnosis and treatment of neuropathic pain.   
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CHAPTER 2 
Prevalence of Neuropathic Pain 
 
Nomenclature 
A fundamental requirement for identifying the prevalence of neuropathic pain in society is 
that clinicians and epidemiologists agree to a uniform classification. Unfortunately, 
neuropathic pain in the orofacial region has been described with different terminology by 
various investigators over the years. Originally, the condition was described as atypical 
odontalgia (AO) in response to the atypical nature of the condition: this term was 
subsequently listed in the Taxonomy of Chronic Pain Syndromes by the IASP (1). Other 
terms have included idiopathic odontalgia (21), neurovascular odontalgia (22), and 
phantom tooth pain (5). More recently, neuropathic pain (oral neuropathic pain / 
neuropathic orofacial pain) has been the preferred term, and is based on the criteria of the 
condition’s underlying pathophysiology (3, 4, 8, 23). However, it is important to point out 
that neuropathic orofacial pain is an all embracing term and that several subsets may exist 
according to the location and aetiology of the neuropathic pain. For example, AO or 
phantom tooth pain implies pain in the mucosa at the site of a tooth extraction, often with a 
history of frequent previous restorative and endodontic procedures having been carried out 
on the tooth in question preceding extraction. Other locations of pain may be the mucosa 
and gingivae as a result of periodontal therapy, but it is difficult to say whether the pain has 
arisen in the periodontal tissues from scaling procedures, pulpal stimulation, or both. More 
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recently, there is preliminary evidence to suggest that burning mouth / tongue syndrome 
(glossodynia, glossopyrosis) may be another form of neuropathic pain (24). 
 
Prevalence and incidence 
The prevalence of neuropathic pain varies according to the site and type of surgery, age of 
the patient, and co-existing medical conditions. Neuropathic pain is observed in several 
different medical conditions including postherpetic neuralgia, phantom limb / stump pain, 
post-spinal cord injury pain and complex regional pain syndromes. The incidence of 
neuropathic pain varies according to the underlying causal factor. As examples, 
postherpetic neuralgia occurs in up to 75% of elderly patients with zoster infection but only 
10-15% of the younger age group who suffer the condition; between 2-97% of patients 
may develop post-amputation pain in the limb (phantom limb pain) (25); 60% of patients 
with traumatic spinal cord injury have pain one year after the event; complex regional pain 
syndrome type II (previously termed causalgia) occurs in 2-5% of patients after peripheral 
nerve injury. Other causal factors in the peripheral nervous system (PNS) include malignant 
invasion of nerves and direct trauma to a nerve such as crush injury (neuropraxis), section 
or cutting (neurotmesis), or stretch / avulsion. Central nervous system (CNS) trauma, 
tumour and ischaemia can also be responsible for the development of neuropathic pain.  
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The incidence of neuropathic pain following surgery is estimated to be 1-2% but probably 
varies according to the type of operation e.g. increased incidence post-thoracotomy (26). 
Postoperative neuropathic pain is more prevalent following amputation when there is 
concurrent pain, and when there has been severe postoperative pain. A review of patients 
conducted at the author’s institution, a multidisciplinary pain centre (Pain Management and 
Research Centre (PMRC), University of Sydney), revealed that 14% of the patients with 
neuropathic pain referred to the chronic pain service listed surgery as the causal factor, and 
that 1-2% of postoperative patients referred to the acute pain service described features of 
neuropathic pain (C. Hayes, unpublished data, PMRC). In surgical patients, 43% of 
postmastectomy patients reported recurrent / persistent pain with age being an important 
variable (65% in the 30-49 year age range, 40% in 50-69 years, and 26% in 70+ years) 
(25). Postherpetic neuralgia is described as the most common form of neuropathic 
orofacial pain, identified in 17 patients (0.3%) out of 5,000 patients referred to a medical 
pain management clinic (9). The incidence of postherpetic neuralgia (all anatomical 
locations) is 125 per 100,000 of the population (27). In Charcot-Marie-Tooth disease, a 
hereditary sensori-motor neuropathy, 71% of patients were reported to develop 
neuropathic pain (28). Not surprisingly, a novel area of research for predicting risks 
associated with developing chronic pain has focused on the role of genetic factors (29).  
 
No formal prospective studies have been carried out to assess the extent of neuropathic 
orofacial pain. The only available information  consists of several retrospective studies 
investigating potential causal factors. One study examined the possible role of endodontic 
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procedures in triggering the condition but was limited in drawing conclusions as it only 
investigated chronic pain in patients from one endodontist (17). However, the findings at 
least provide a window regarding the possible extent of the condition. In the study, 732 
questionnaires were mailed out to patients who had completed endodontic treatment from 
one endodontist, with 463 (63%) useable responses. The investigators found 3% of female 
patients met all four criteria of phantom tooth pain, including no obvious physical or 
radiographic abnormalities, and 6% manifested three out of four criteria. An interesting 
aspect of this study, and one that limited the analysis of the problem, was the reluctance of 
four other endodontists to participate in the study. The non-participating endodontists had 
remarked, “Perhaps our greatest anxiety, however, is over the fact that a Pandora’s box 
would be opened up.” A later publication by the same author (3) extrapolated these earlier 
findings and suggested that neuropathic orofacial pain (from endodontic procedures) may 
be present in some 125,000 individuals in the USA alone. In another study that reviewed 
118 patients who had completed surgical endodontics, six patients (5%) had persistent 
pain following surgery, three patients had pain before the surgery but there was no 
postoperative pain reduction, and three patients developed pain following surgery (30). 
Other researchers have examined the prevalence of neuropathic pain following dental 
extractions in patients with frequent headaches (31). In this study, for the cohort with 
headache (n = 301), pain in the edentate site was reported by 20% of patients suffering 
from cluster headache and 14% of patients suffering migraine. The authors also found that 
the more teeth that had been extracted, the greater the pain, and the incidence of 
neuropathic pain was directly proportional to the number of teeth extracted. In contrast, 
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there was no patient reporting persistent post extraction pain in the healthy control group (n 
= 280, no history of recurrent headache). In a cohort of patients with chronic idiopathic 
orofacial pain, dental therapy was associated with the onset of pain in 28/50 cases (32). 
Another study analysing patients with chronic orofacial pain (n = 120) revealed that 25% 
of patients were diagnosed with AO (33). 
 
A potential issue in determining the extent of the problem has been the difficulty faced by 
various practitioners and investigators in diagnosing pain conditions, or in obtaining a 
correct diagnosis. For example, one study reported that there was no clearly identifiable 
cause in 38% of patients in a chronic orofacial pain group (34), and another study of 
several case reports described patients as having a diagnosis of atypical facial pain (or 
atypical facial neuralgia), yet these patients clearly fulfilled the description of neuropathic 
orofacial pain (35). It is plausible that other patients are misdiagnosed, thus underestimating 
the prevalence of neuropathic pain. A study of a group labelled as chronic idiopathic 
orofacial pain patients, whose features were suggestive of a diagnosis of neuropathic pain, 
revealed that 15% of the patients had evidence of post-traumatic stress disorder that 
coincided with the onset of pain (36). 
 
Psychological factors may well play a part in the development of neuropathic pain through 
unrealistic expectations of treatment. One report found that 65% of chronic pain patients 
(back, neck and limb) still had strong beliefs in the possibility of medical cure (including 
further surgery) for their pain despite an average of 9.7 years of pain and, of these patients, 
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60% had evidence of overinvestigation and / or overtreatment (37). Thus, in some cases of 
neuropathic pain, psychological variables may be indirectly responsible for the 
development of the condition through unnecessary additional treatment that is possibly the 
direct causal factor. The prevalence of neuropathic orofacial pain has been estimated to be 
up to 125,000 patients in the USA,  perhaps an extraordinary claim (3). However, it 
should be noted that the majority of people with chronic pain (for example, patients with 
back pain) do not, in fact, seek extensive investigation and treatment, and there may well 
be a silent majority of orofacial pain patients as alluded to by Marbach (3). 
 
The reason that patients seek treatment for a chronic pain complaint is complex and 
multifactorial. It may involve pain relief, by reducing peripheral nociception and sensory 
aspects of neuropathic pain, altering the perception of pain information in central areas, and 
it may involve the management of suffering (or psychological distress). 
 
Further prospective studies evaluating the prevalence of neuropathic orofacial pain are 
warranted. In particular, studies concerning the specific association or development of 
neuropathic pain from endodontic procedures may prove valuable in a greater 
understanding of causal factors as a clinical model for medical variants of neuropathic pain.  
 
CHAPTER 3 
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Neurobiology of Pain: the Progression from the Acute Pain Phase 
to Chronic Neuropathic Pain 
 
Pain serves as a protective function by providing an early warning of potential tissue 
damage, thus leading to the initiation of appropriate withdrawal reflexes. ‘Physiological 
pain’ is transient and well localised, and the individual can differentiate between pain 
transmitted by C and A-d fibres, and touch transmitted by A-b  fibres. In addition, pain 
initiates complex neurohumoral responses that help to maintain homeostasis in acute injury 
and pain. The response to tissue damage is similar irrespective of the injury such as a 
surgical incision, traumatic injury (e.g. fracture), soft tissue damage, disease processes (e.g. 
infection, cancer), and burns. While the degree of trauma and pain may be expected to 
correlate with the degree of the injury, there is a wide individual variation in the response to 
an injury, with evidence indicating that both physiological and psychological factors are 
involved.  
 
While most pain from injury proceeds through an orderly course, there is the potential for 
the development of vicious cycles of pain. Even a seemingly innocuous stimulus such as a 
small incision or a tooth extraction may cause a chronic pain state. Unfortunately, there is 
no accurate technique that can predict those patients who will develop any type of a 
chronic pain state including neuropathic pain in the orofacial region. Chronic pain is defined 
as pain that has been present for longer than three months (1). Biological processes 
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involved in chronic pain may occur within hours to days of an injury, and acute severe pain 
lasting for only ten days can lead to chronic pain. Events that occur following injury include 
peripheral sensitisation, and subsequent neuronal plasticity involving the peripheral, central 
and sympathetic nervous systems. Depending on the severity of trauma, peripheral 
sensitisation and areas of the CNS may be activated, leading to persistent or 
pathophysiological pain. The following summary of pain mechanisms is based on a recent 
extensive review (38).  
 
Peripheral sensitisation 
An acute injury leads to the Lewis triple response of oedema (wheal), vasodilation (flare) 
and pain. There is an antidromic response (towards the periphery) along collaterals of 
primary afferent fibres that results in the local release of chemical mediators to cause an 
increased response to the noxious stimulus. Nociception primarily involves activation of C 
fibre afferents by thermal, chemical and mechanical stimuli. The triple response of Lewis 
describes the sequence of events at the site of injury, and involves the PNS. During 
inflammation there is a release of intracellular contents from damaged cells and 
inflammatory cells including macrophages, lymphocytes and mast cells. Nociceptive 
stimulation also causes the release of peptides such as substance P, neurokinin A and 
calcitonin gene-related peptide from primary afferent terminals (39). These peptides alter 
the excitability of nociceptors (and sympathetic fibres), and induce vasodilation and 
extravasation of plasma proteins, and cause inflammatory cells to release chemical 
mediators. This produces a ‘sensitising soup’ of inflammatory mediators, including reactive 
  29
oxygen species, histamine, cytokines, potassium, serotonin, bradykinin, nitric oxide, 
leukotrienes, and prostaglandins and enzymes from the cyclooxygenase and lipoxygenase 
pathways. Following sensitisation, painful stimuli are perceived from low intensity, 
mechanical stimuli that are not normally painful, a condition termed allodynia (1). 
Furthermore, hyperalgesia may develop in adjacent tissues, hyperalgesia being defined as 
an increased response to painful stimuli (1). Noxious skin stimuli sufficiently intense to 
produce tissue injury usually generate prolonged post-stimulus sensory disturbances 
including allodynia and hyperalgesia. Hyperexcitability, in part, arises from changes in 
activity of the spinal cord. Long term consequences of pain thus result from both peripheral 
and central changes. These changes result in disturbance to the area of injury (primary 
hyperalgesia) but also to undamaged adjacent areas (secondary hyperalgesia and referred 
pain) (Figure 1). 
 
Several factors have been demonstrated to be involved in the development of this form of 
pain (38). First, brief stimulation of peripheral, unmyelinated, afferent fibres can produce 
substantial and prolonged changes in the cutaneous receptive fields of dorsal horn neurons. 
The response of dorsal horn neurons can be influenced by the history of previous noxious 
stimuli. Second, repetitive peripheral stimulation results in a progressive increase in 
response of dorsal horn neurons, termed windup, and continued  firing, termed  after  
discharge.  After  discharge is  four  times longer in a  
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Figure 1. Neuronal plasticity, primary and secondary hyperalgesia, and allodynia. A 62-
year-old female with neuropathic pain of ten years duration that demonstrates neuronal 
plasticity in the form of primary and secondary hyperalgesia, and allodynia. The original site 
of pain was the extraction of 35, soon followed by 27 (marked X). Primary hyperalgesia is 
demonstrated by ipsilateral areas on the floor of the mouth and labial mucosa adjacent to 
35, and the cheek mucosa and ipsilateral palatal region adjacent to 27. Secondary 
hyperalgesia is demonstrated on the dorsal surface of the tongue and other regions on the 
contralateral side. 
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stimulated, sectioned peripheral nerve compared with an intact nerve. Third, in the 
presence of an intact nervous system, noxious C afferent fibre input usually does not 
produce prolonged excitability of the flexion reflex (in rat studies) (40). In contrast, noxious 
muscle stimulation does produce prolonged changes in the reflex. Consequently, muscle 
trauma and spasm that can produce local ischaemia and inflammation may cause changes 
at the spinal level, leading to the development of a vicious cycle of enhanced muscle spasm 
and progressive increases in pain and the injury response. Fourth, the mechanism of long 
lasting changes in excitability of spinal neurons is related partially to N-methyl-D-aspartate 
(NMDA) receptors, with second messengers such as calcium, cyclic AMP and 
diacylglycerol that trigger prolonged changes. In addition, third messengers such as c-fos 
permit genetic encoding of an altered pattern of enhanced responsiveness of dorsal horn 
neurons. 
 
NMDA receptor activation can cause facilitation, windup, central sensitisation, and 
changes in peripheral fields and induction of oncogenes. At the level of the CNS, 
neuropathic pain can be seen through a well studied marker, c-fos expression. Fos is a 
protooncogene protein that can be measured by immunoreactivity. It targets genes, leading 
to genetic changes and subsequent long term responses e.g. to pain. It is induced in spinal 
cord neurons by noxious stimuli. Innocuous peripheral stimuli can also induce c-fos 
expression, but to a very limited extent; for example, capsaicin administration in an acute 
inflammation model showed c-fos expression to be present for less than 24 hours. In 
animal studies of pain, inflammation and drug pharmacodynamics (i.e. the effect of the drug 
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on the body) using rat spinal cord, c-fos expression is induced or modulated in various 
laminae. With peripheral stimulation, the superficial laminae (I-II) of the spinal cord exhibit 
c-fos expression. However, in the case of allodynia in the rat model, the presence of Fos 
protein in the deeper laminae is elicited, indicating the involvement of A-b  afferents (41). c-
fos activation thus provides important information on possible central mechanisms of 
neuropathic pain and the potential benefits of preemptive drug treatment. For example, 
intravenous morphine and morphine administered to the peripheral injury site have been 
shown to significantly decrease c-fos expression from intraplantar carrageenin in the rat. 
Other drugs demonstrating an effect on the presence of Fos protein include local 
anaesthetic (lignocaine and bupivacaine), opioid (remifentanil), glucocorticoid 
(dexamethasone), and nonsteroidal antiinflammatory drugs (NSAIDS) (ibuprofen).  
 
Neuronal plasticity 
Pathophysiological pain such as neuropathic pain can be explained, in part, by nervous 
system plasticity. Patients with neuropathic orofacial pain often describe multiple sites of 
pain in teeth across all quadrants although the initiating event has been a dental procedure 
in a single tooth (Figure 2). Neuroplasticity may also occur at the peripheral and / or spinal 
cord level; for example, damaged nerve fibres may produce neuromas. Nerve growth 
factor, a peptide that regulates neuronal growth, is a prime initiator of nerve sprouting that 
is involved in neuroplasticity and may play a role in altering responsiveness to sensory 
input. Peripheral abnormalities can result from  sensitisation of  nociceptors or  axon 
damage, permitting  ectopic  locations for 
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Figure 2. Multiple sites of pain in teeth demonstrating neuronal plasticity. A 45-year-old 
female with neuropathic orofacial pain of 18 months duration. The intraoral pain map 
indicated multiple sites of pain in teeth in both (a) maxilla, and (b) mandible, that had no 
radiographic or clinical pathology. 
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spontaneous neuronal discharge (peripheral neuromas). These changes may also occur 
along the course of axons and produce microneuromas. Neuromas are capable of 
spontaneous discharge, greatly enhanced and prolonged discharges, and show minimal 
accommodation. Properties of neuromas include sensitivity to mechanical stimuli, 
spontaneous firing and sensitivity to noradrenaline. The sensitivity of neuromas appears to 
be related to the time since nerve injury, being most intense within the first two weeks of 
neuroma formation, but then maintained at a lesser, continued level. Clinically, this situation 
is recognised by the production of intense, electric, shock-like pain at the site of the 
neuroma, and radiating pain on percussion of the neuroma (Tinel’s sign). Damage to axon 
sheaths may also result in demyelination, resulting in nerve hyperexcitability. This causes 
paroxysms of pain and afferent activity may initiate reflex motor activity causing muscle 
spasm. This may account for the development of a temporomandibular disorder (TMD) 
that is secondary to the primary neuropathic oral pain (Figure 3). Evidence has shown that 
peripheral neuroma pain may not be blocked by local anaesthetic at the site, suggesting that 
central mechanisms are involved (42). In the clinical situation of patients with neuropathic 
oral pain there is a wide range of responses to topical anaesthetic application, with patients 
demonstrating either complete, partial or no pain reduction to somatosensory blockade 
(43, 44). Evidence from animal studies suggests that there is a genetic predisposition in the 
development of spontaneous activity in neuromas. In the clinical situation, patients who 
develop neuromas frequently have similar problems after attempts to remove them (42). 
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Figure 3. Development of temporomandibular disorder secondary to neuropathic pain in 
two patients:  (a) myofascial pain was initially restricted to the left masseter muscle and 
over the course of several years it spread to involve the left shoulder, lower thoracic and 
lower lumbar / sacral regions, (b) description of neuropathic intraoral pain of three years 
duration with subsequent involvement of masseter, temporalis and semispinalis capitis 
muscles.  
 
 (a) 
(b) 
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In summary, the latter stages of injury involve invasion of the damaged area by phagocytes 
and fibroblasts. Damaged nerve endings and capillaries sprout and infiltrate into the area 
where sensory, sympathetic and motor fibres are already present. C fibres are involved in 
detecting the altered chemical environment, a phase that coincides with the beginning of 
scar formation, and the patient’s probable awareness of a persistent pain problem.  
 
Sympathetically maintained pain 
Another development in neuropathic pain may be abnormal, ongoing sympathetic activity, 
termed sympathetically maintained pain (SMP). SMP is defined as pain that is maintained 
by sympathetic efferent innervation or by circulating catecholamines. The pathophysiology 
of SMP probably involves coupling between sympathetic and somatosensory pathways. 
This has been postulated to occur at peripheral nociceptors, at the dorsal root ganglion 
with subsequent sprouting of noradrenergic perivascular axons, and at central spinal cord 
sites. Both direct and indirect methods of excitation of peripheral nociceptors by 
noradrenaline have been proposed (45). Following nerve damage or chronic inflammation, 
a subset of C-polymodal nociceptors has been shown to develop sensitivity to sympathetic 
stimulation, and thus, may be directly stimulated by noradrenaline. Alternatively, 
noradrenaline may act indirectly via release of prostaglandins that, in turn, sensitise the 
nociceptor. Inflammation may also induce nociceptor sensitivity to noradrenaline. In 
considering endodontic and other dental procedures, the practitioner should be aware of 
the possibility, or indeed the likelihood, of preexisting gingival / periodontal / periapical 
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inflammation and the potential for the interaction of noradrenaline in dental anaesthetic 
cartridges.  
 
SMP may also involve central mechanisms that could explain the development of 
hyperalgesia and more generalised pain. Pain transmission pathways may undergo plasticity 
through changes in receptor sensitivity, genetic changes and neuroanatomical 
reorganisation, leading to central sensitisation and windup. C-polymodal nociceptors can 
activate and sensitise wide dynamic range neurons; these then respond to activity in large 
diameter A-mechanoreceptors that are activated by light touch. The pain threshold is 
reduced, and previous subthreshold stimuli are then perceived as painful (i.e. hyperalgesia). 
This explains the frequent observation in neuropathic oral pain patients that they cannot 
tolerate wearing a denture following extraction, particularly where the denture saddle rests 
upon an area of allodynia or hyperalgesia.    
 
There is now an increased awareness of the role of the sympathetic nervous system in a 
variety of neuropathic pain states such as postherpetic neuralgia, CNS lesions and 
amputation (phantom pain) syndromes (46). SMP has been linked in the past with reflex 
sympathetic dystrophy and causalgia, now designated Complex Regional Pain Syndromes 
(CRPS) types I and II, respectively. CRPS is a clinical diagnosis that may include, but 
does not imply, an underlying component of SMP. The main feature of CRPS is pain (with 
associated allodynia / hyperalgesia) that is disproportionate in severity to the inciting event 
and occurs in a regional distribution beyond the territory of a single peripheral nerve. In 
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CRPS there may be associated oedema, changes in blood flow, abnormal sudomotor 
activity such as sweating, and motor dysfunction (Figures 4, 5). The present IASP 
taxonomy does not include a category for CRPS type I involving orofacial locations; 
however, there is clear clinical evidence of sympathetic nervous system involvement in 
neuropathic orofacial pain (Figures 4, 5) (8, 9). Although SMP may be a component of the 
patient's pain syndrome, it is often impossible to predict and distinguish, on the basis of 
presenting symptoms alone, those who will benefit from sympatholytic procedures (47).  
 
Gender issues in pain in the orofacial region  
Numerous factors are thought to play a pivotal role for gender differences in patients with 
pain (48), particularly the greater prevalence of women with orofacial pain conditions that 
appears to involve neurobiological and psychological aspects. It  has been reported that 
there is  a significantly greater prevalence of women (88:32) with chronic orofacial pain 
presenting at a pain management centre (33). Specifically, those patients with pain of 
idiopathic onset and marked psychosocial variables (previously termed atypical facial pain) 
were significantly higher (34:6). For a group diagnosed with neuropathic orofacial pain 
(including atypical odontalgia) the female : male ratio was 34:16 (8). In comparison, the 
female : male ratio of general body pain conditions such as back pain and phantom limb 
pain at the same institution was 45:55. Women report more multiple or recurrent pains than  
men,  particularly  more  at  certain  ages  and  certain  body regions (49). In, 
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Figure 4. Sympathetic hyperfunction secondary to neuropathic pain. A 58-year-old female 
with neuropathic pain on the right side of the face after dental treatment in the right maxilla: 
(a) left side of face with normal complexion (b) sympathetic hyperfunction (redness) in the 
right cheek region “nearly always present and needs cosmetic applications to mask it”, (c) 
frontal photograph for comparison.   
 
     (a) 
 
 
 
 
 
 
 
 
 
 
 
(b) 
(c) 
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Figure 5. Recurrent sympathetic nervous system involvement. A 55-year-old female patient 
with a three year pain history: (a) normal facial appearance, (b) episode of sympathetic 
nervous system involvement characterised by swelling and an increase in pain intensity in 
the left cheek region. There is a noticeable loss of the left nasolabial crease that persisted 
for several days. 
 
     (a) 
 
 
 
(b) 
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particular, there is an increased prevalence of recurrent or chronic pain syndromes in the 
head and neck region for females compared with males (Table 1) (50).  
 
Gender differences exist in pain intensity in acute orofacial pain. In a third molar surgical 
extraction study females reported higher baseline pain ratings than males (average visual 
analogue scores of 7 and 4.7, respectively), but administration of kappa-opioid agonists 
(nalbuphine, butorphanol) produced significantly greater pain relief and a longer duration of 
action for females than males (51). In contrast, in the chronic situation, there is no 
significant difference in pain intensity for gender as measured by numerical rating scales and 
the McGill Pain Questionnaire (33). A possible explanation may be found in oestrogen 
concentrations. Oestrogen is known to modulate opioid mechanisms by increasing 
endogenous opioid activity (52) and to regulate central expression of nerve growth factor 
(53), both important mechanisms in the development of neuropathic pain.  
 
Psychological differences in the expectation of pain also exist. Male children have been 
shown to underestimate, and female children overestimate, the expected pain of impending 
venepuncture, yet pain ratings were similar for the actual procedure (54). In a study 
assessing psychological variables in patients with osteoarthritis, there were significant 
differences in pain, pain behaviour, and physical disability between men and women. 
Women had significantly higher levels of pain and physical disability,
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Table 1. Prevalence of recurrent or chronic pain syndromes in the orofacial, and head and 
neck region (modified from Berkley KJ, Holdcroft A. Sex and gender differences in pain. 
In: Wall PD, Melzack R, eds. Textbook of Pain, 4th ed. London, Churchill Livingstone, 
1999, p. 952) (50). 
 
 
 
 
Female prevalence 
 
Male prevalence 
 
No sex prevalence 
migraine with aura migraine without aura acute tension headache 
chronic tension headache cluster headache maxillary sinusitis 
cervicogenic headache post traumatic headache acute pulpitis 
trigeminal neuralgia  cracked tooth syndrome 
temporomandibular disorder  dry socket 
occipital neuralgia   
periodontitis   
atypical odontalgia   
burning mouth / tongue 
syndrome 
  
carotidynia   
chronic paroxysmal hemicrania   
temporal arteritis   
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and exhibited more pain behaviour than men. However, once catastrophising was entered 
into the analyses, the previously significant effects of gender were no longer found (55). 
Females and males may not interpret and report sensations in the same way and, 
subsequently, there may be gender differences in the way men and women communicate 
with the surgeon regarding their pain, hurt and suffering. In summary, hormonal, 
neurobiological and psychological (learned) factors have important roles in gender 
differences. Further research into gender is warranted to understand these differences, and 
specifically for the area of orofacial pain.  
 
Summary of features that suggest neuropathic pain  
(modified from the National Health and Medical Research Council. Acute Pain 
Management: Scientific Evidence. AusInfo, Canberra. 1998; pp. 11-12) (56). 
· Pain in the absence of ongoing tissue damage 
· Pain in an area of sensory loss 
· Paroxysmal or spontaneous pain 
· Allodynia, hyperalgesia and dysaesthesia 
· Delay in onset of pain following injury or surgery of weeks or months (NB some 
neuropathic pain has immediate onset) 
· Poor analgetic response to opioids 
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 CHAPTER 4 
 
Diagnostic Procedures and Treatment Guidelines 
 
A correct diagnosis for patients with neuropathic pain is vital for administering the 
appropriate treatments and management strategies. Factors contributing to chronic pain fall 
into three broad categories: nociceptive, neuropathic and psychological / environmental. It 
is imperative to diagnose which category (or categories) of pain the patient presents with, 
because the treatments vary. Furthermore, the large majority of patients may display 
multiple co-existing factors. For example, a patient with neuropathic pain may have 
significant psychosocial factors modulating the pain, and then, in addition, have nociceptive 
pain from surgery performed in an attempt to ‘cure’ the existing pain. Nociceptive factors 
result from stimulation of nociceptors by tissue damaging (noxious) stimuli where the 
nervous system is intact, such as early dental infection / pulpitis. Neuropathic pain results 
from damage, disease, or complete section (deafferentation) of the PNS or CNS in the 
absence of a peripheral noxious stimulus. Psychosocial and / or environmental factors may 
predominate when no detectable noxious stimulus or damage to the nervous system is 
present and pain behaviour is presumed to arise primarily from these factors.  
 
A patient with chronic pain may develop, in addition to his / her current complex 
biopsychosocial problem, further problems such as myofascial pain (57). In particular, in 
the case of neuropathic orofacial pain, it is likely that two out of three patients will develop 
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a secondary TMD (8). Iatrogenic causes may play an important role in the further 
development of neuropathic orofacial pain (Figure 6). For example, a dental practitioner 
may provide treatment in a tooth or site of pain where there is no obvious clinical or 
radiographic abnormality, thereby aggravating any resident neuropathic pain problem.   
 
Neuropathic pain is often reported by patients to be severe, and can be accompanied by 
significant levels of distress. Moreover, the impact of the pain is not confined solely to the 
afflicted patient. The scope of changes attributed to chronic pain includes lost work 
productivity, reduced levels of social activities, and behavioural changes in the patient, 
spouse and family (Figure 7). It is now well recognised that early intervention can play a 
major role in achieving more successful outcomes for patients. The basis of early 
intervention with its appropriate treatment(s) relies on a correct and early diagnosis utilising 
validated methods and tests. In addition, the prognosis of neuropathic orofacial pain is 
dependent on curtailing the traditional Cartesian approach to painful sites where the 
concept is that the removal or amputation of the suspect site (tooth) will lead to the 
resolution of the pain (Figure 6). This approach causes further iatrogenic problems by 
worsening the patient’s current (neuropathic) pain problem. Moreover, the development of 
a TMD secondary to the neuropathic pain occurs through neuronal circuits and the 
unnecessary extraction of teeth with a resultant malocclusion. 
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Figure 6. Iatrogenic dental procedures in a patient with neuropathic pain. A 33-year-old 
female patient with a three year history of neuropathic pain reporting her compilation of 
dental procedures (n > ten procedures) carried out by several dentists over a nine month 
period to ‘cure’ the pain. 
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Figure 7. Effects on the family of a patient with neuropathic pain. Letter sent by family 
member (patient’s daughter) detailing the range of effects on the family and business.  
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Consequently, specific diagnostic tests are crucial to engage early interventional treatments 
and to avoid iatrogenic spread of the pain. 
 
Recommended diagnostic procedures 
1. Pain history 
In addition to a routine medical history and clinical examination, there is the need to obtain 
specific information in relation to a pain history. Pain maps are useful to delineate the origin 
of the pain and subsequent areas of radiation. The following information should be sought 
in a pain history based on the National Health and Medical Research Council guidelines for 
pain management (56):  
· Circumstances associated with pain onset 
· Primary site of pain 
· Radiation of pain 
· Character of pain 
· Intensity of pain (at rest, at present, during last week, highest level) 
· Factors altering pain (what makes it worse, what makes it better) 
· Temporal quality (continuous, periodic, intermittent) 
· Effect of pain on activities 
· Effect of pain on sleep 
· Medications taken for pain 
· Other treatments used for pain 
· Health professionals consulted for pain treatment 
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· Patient’s knowledge, expectations and preferences for pain management  
· Patient’s beliefs as to the cause of the pain 
· Reduction in pain required to resume reasonable activities 
· Presence of depression, anxiety or psychiatric disorder 
· Family expectations 
· Ways the patient describes or shows the pain 
 
2. Pain measuring instruments 
The visual analogue scale (VAS) is a simple, pencil and paper instrument that is used by 
the patient to quantitate pain intensity. In addition, the VAS can be incorporated into daily 
pain intensity log charts to view the efficacy of a diagnostic or treatment trial. Analogue 
scales have been shown to demonstrate reliability, validity and versatility (58). Variations of 
the VAS exist and a comparison of analogue scales has revealed that graded numerical 
rating scales (NRS) are more reliable than descriptive analogue scales (59). An evaluation 
of various length and end-phrase variations of the VAS has shown that the ten cm VAS 
exhibits the smallest measurement error, while the end-phrase “worst pain imaginable” 
provides the greatest sensitivity in measuring present pain in patients with dental pain (60). 
The VAS is useful for both chronic and experimental pain (61). 
 
The description of a pain condition (i.e. the patient’s choice of words applicable to the 
qualities of the pain condition) can provide simple but valuable information for diagnosis, 
selection of appropriate drugs, and levels of psychological distress. The MPQ is another 
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pencil and paper pain measuring instrument that allows the patient to select appropriate 
pain word descriptors. It can measure pain intensity through various indices including 
sensory and affective components of pain. The MPQ has been used for evaluating acute 
(postoperative) orofacial pain from third molar surgery (62). In addition, the MPQ has 
been used to assess acute toothache patients and was able to differentiate different stages 
of pulpitis (irreversible versus reversible), with a correct prediction rate of 73% in subjects 
(63). Similar findings have been reported in using the MPQ to differentiate pulpitis from 
pericoronitis (64). One study assessed the utility of the MPQ for analysing chronic 
orofacial pain conditions; two chronic orofacial pain conditions were examined, atypical 
facial pain and trigeminal neuralgia, and the authors correctly predicted the diagnosis in 
90% of patients (65). The MPQ has a standard form that was designed by Melzack (66) 
and the form consists of 78 words categorised into 20 groups, representing the four major 
dimensions of pain quality: sensory, affective, evaluative and miscellaneous pain 
descriptors. These groups of words are scored and ranked to furnish four indices of pain 
quality; pain rating index of sensory descriptors (PRI(S)), pain rating index of affective 
descriptors (PRI(A)), pain rating index of evaluative descriptors (PRI(E)) and the pain 
rating index of miscellaneous descriptors (PRI(M)). The four pain rating scores can then be 
added to give a fifth index, the total pain rating index (PRI(T)).  
 
3. Local anaesthetic techniques 
A positive response (pain reduction) to somatosensory blockade of pain sites by various 
routes of administering local anaesthetic agents is suggestive of neuropathic pain (and 
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nociceptive pain). In the orofacial region, the area can be tested by several techniques to 
determine possible sources of the location of pain. Ideally, these local anaesthetic agent 
techniques should be employed in a controlled, patient blinded manner, i.e. incorporating 
the use of placebo injections (placebo responses occur in up to 60% of patients with 
neuropathic pain). First, the administration of a topical anaesthetic to mucosal pain sites is 
advantageous by being non-invasive, with a study revealing that 37/38 patients with 
neuropathic pain responded with a reduction in pain when a topical anaesthetic cream was 
applied for five minutes (8). The topical anaesthetic of choice is EMLA cream 5% 
(AstraZeneca, Sydney, Australia) which is a eutectic mixture of lignocaine and prilocaine 
bases. The eutectic mixture has a low melting point of 170C and is an oil at mouth 
temperature, thus facilitating absorption. The agent has been shown to have rapid oral 
mucosal absorption, to penetrate deeply into the oral tissues, and to be safe from toxicity 
from extended application times of up to 30 minutes (67, 68). It is superior for sensory 
blockade compared with lignocaine 5% and 10% ointments (Xylocaine 5% and Xylocaine 
10% Special Adhesive) and a benzocaine / amethocaine mixture (NUM) (67). The 
technique involves obtaining a VAS for basal pain intensity, followed by the removal of 
excess saliva from the test site using fresh cotton gauze. Isolation and placement of a 
placebo such as petroleum jelly on a cotton bud for five minutes follows, and another VAS 
is obtained. The placebo is then wiped off and a liberal quantity (1 g) of EMLA applied for 
five minutes and a final VAS measured. The VAS responses can then be assessed to 
determine comparative pain reduction with EMLA. 
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Further local anaesthetic blockade can then be used to confirm other possible locations of 
peripheral neuropathy. This should be performed with sequential proximal anatomical 
blocks. For example, in testing the mandibular canine region, the analgetic sequence would 
be EMLA, mental nerve block, mandibular block using the ‘conventional’ technique 
blocking the mandibular nerve at the mandibular foramen, then a high mandibular block 
using either the closed mouth or Gow-Gates techniques (69, 70). The Gow-Gates block 
has been shown to be more effective for producing analgesia but the closed mouth 
technique, also termed the Akinosi block (71), is a more acceptable technique to patients 
according to reports (72). This provides potentially valuable information as to the location 
of any neuroma formation, and thus the likely success of utilising topical antineuropathic 
agents such as capsaicin. Obviously, in the situation of a patient who is a non-responder to 
all blocks, there is the likelihood of CNS changes (centralisation of pain). Hypothetically, 
the probable selection of plain lignocaine (1-2%) as the test agent is preferable to 
lignocaine with vasoconstrictor (adrenaline / noradrenaline combinations) because of the 
potential for noradrenaline and protons (low pH of solution) to actually increase pain 
before the onset of neural blockade from lignocaine in the dental anaesthetic cartridge.  
 
Three types of patient blinded, controlled local anaesthetic techniques are available. The 
first technique involves using normal saline as a control agent followed by a local 
anaesthetic agent such as plain lignocaine (1-2%), obtaining VAS measures at baseline 
(prior to saline injection), five minutes after the saline block, and five minutes after the local 
anaesthetic block. The second technique is more robust and utilises two local anaesthetics 
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with different systemic absorption rates. The first block utilises plain lignocaine, then at a 
later stage, plain bupivacaine (0.025-0.5%). Bupivacaine has a slower absorption rate than 
lignocaine and a positive response would show pain reduction with both agents, but a 
longer period of pain reduction using bupivacaine. A third, superior technique, if time 
permitted, would employ triple patient blinded blocks: the first injection using normal saline, 
the second using plain lignocaine, and the third using plain bupivacaine. 
 
The intravenous lignocaine test requires referral to a specialist pain clinic with the services 
of an anaesthetist / pain specialist. This test has been reported to be useful in discriminating 
neuropathic pain from other forms of chronic pain (73). The test involves an infusion of 
lignocaine in increments up to a maximum of 2 mg/kg. It is placebo controlled and only one 
study has tested its application for neuropathic orofacial pain. In a test group of eight 
patients, 50% had a positive response with an average pain reduction of 68±10%. 
Interestingly, all the negative responders had a history of endodontic therapy in the area of 
pain but no further details were reported by the investigators to draw conclusions (73).  
 
4. Sympathetic procedures 
A thorough clinical history can identify those patients with a component of SMP. Clinically, 
the patient may give a history of episodes of oedema involving the face, and occasionally 
with a hot or burning quality. The clinician should ask the patient whether or not he /she 
experiences episodes of swelling in the face. An affirmative response warrants referral for 
more definitive tests such as the phentolamine infusion.  
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A diagnosis of SMP is made when the pain is relieved by sympathetic blockade. However, 
there is no single test with adequate sensitivity and selectivity to distinguish SMP from 
sympathetically independent pain (SIP). The sympathetic chain receives efferent 
preganglionic fibres from the ventral roots of T1 (first thoracic nerve root) to L2 (second 
lumbar nerve root) and forms the stellate ganglion, thoracic paravertebral chain, coeliac 
plexus, lumbar paravertebral chain and superior hypogastric plexus. The sympathetic 
supply in the orofacial region originates from the stellate ganglion located in the neck. 
Studies using thermography (74, 75) and stellate ganglion block (9) have implicated SMP 
as occupying a role in neuropathic orofacial pain. Stellate ganglion block has been used as 
a diagnostic test for SMP in head, neck and upper limb (76). However, limitations of 
stellate block include false positive responses (spread of local anaesthetic to somatic 
fibres), false negative responses (incorrect placement of local anaesthetic), and an inability 
to conduct blinded, placebo controlled injections (47). The intravenous administration of 
phentolamine (a-1 and a-2 adrenoceptor antagonist) has been utilised as a diagnostic test 
for SMP and a positive response (pain relief) may be predictive of the success of a 
subsequent series of sympathetic blocks (77). In addition, the phentolamine test has the 
advantages of being less invasive and less painful, and blinded, placebo controlled infusions 
can be administered. A specialist anaesthetist must perform the test and patients are 
monitored with electrocardiography, pulse oximetry, and non-invasive blood pressure. The 
test involves the initial administration of 500 mL of intravenous normal saline (0.9%) to limit 
potential hypotension from phentolamine. VAS scores are recorded at baseline and at five 
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minute intervals. During the trial, a saline placebo is infused over ten minutes followed by 
phentolamine 15 mg over ten minutes. If no analgetic response is reported by the patient 
and cardiovascular side effects are minimal (tachycardia and hypotension), further 5 mg 
bolus doses of phentolamine can be administered until a response is observed (pain relief 
or side effects). Only one study has employed the saline / phentolamine test to evaluate the 
sympathetic contribution to neuropathic orofacial pain with results showing that there was a 
significant response to the phentolamine challenge when 75% of patients (9/12) claimed a 
reduction (wide variation) in pain intensity ratings (8). 
 
The involvement of SMP can be assessed by measuring sympathetic hyperfunction through 
changes in skin temperature (thermography and thermometry), blood flow (cutaneous 
Doppler), resting sweat output and the presence of oedema. Electronic thermography has 
been suggested to be useful for SMP, although it is not a readily available test (75). 
However, the technique is promising because it is non-invasive and is selective in thermal 
accuracy (100%), with results showing the affected (painful) side of the face to be hotter 
than the non-painful side (range 0.4-3.10C, mean = 1.1±0.8, n = 10).  
 
Treatment and Pain Management Guidelines 
1. Medication rationalisation 
The selection of appropriate drugs for the treatment of neuropathic pain must take into 
account a number of principles: (i) adequate dose to achieve a therapeutic effect, (ii) 
titration of dose to minimise side effects, (iii) consideration of background medical 
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conditions that may influence the pharmacokinetic profile of the drug, and (iv) drug 
interactions. Drugs appropriate for acute pain management may be, and often are, 
contraindicated for chronic pain management. Polypharmacy may reduce the overall 
amount of drug needed, but the dose must be calculated for each drug given. Blood 
concentrations of drugs may need to be monitored to assess whether therapeutic 
concentrations are being reached. In medication rationalisation, the implementation of 
therapeutic drugs is crucial to effective pain management, yet an equally important task is to 
make recommendations for discontinuing other current, but inappropriate drugs, that are 
often used by patients with chronic pain. In particular, for neuropathic pain, the 
discontinuation of benzodiazepines and opioid drugs is crucial due to issues of central 
sensitisation, tolerance and poor response (Figure 8). Management of neuropathic 
orofacial pain usually entails introducing the oral systemic first-line classes of drugs of the 
tricyclic antidepressants and / or the anticonvulsants. 
 
  57
 
 
 
 
Figure 8. Inappropriate use of drugs for treating neuropathic pain. A single, 46-year-old 
female with neuropathic oral pain of one year duration presented with the following drug 
history. Opioid and nonsteroidal antiinflammatory drugs were trialed by general 
practitioners but were ineffective, a feature with neuropathic pain. She had undergone 
repetitive endodontic therapy (three times) to ‘cure’ the pain and she was “never free from 
pain”. A six week trial of topical capsaicin instigated by the Pain Management and 
Research Centre reduced the pain from 5/10 to 3/10 as measured on the numerical rating 
scale, and she reported the occasional pain free day. Psychological assessment indicated 
background levels of stress and following psychological interventional strategies she has 
reported “no pain at all”.  
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Tricyclic antidepressants 
Tricyclic antidepressants (TCAs) have a valuable role in the management of chronic pain, 
and the institution of a low dose of a TCA such as amitriptyline or nortriptyline as a first-
line drug is frequently employed. Amitriptyline has both catecholaminergic and serotonergic 
activities. The dose is slowly increased from 25 mg nocte for the first week, to 50 mg 
nocte for the second week, and then to 75 mg nocte for the third and ensuing weeks, to 
build up patient tolerance to side effects such as sedation. For the elderly, it is prudent to 
commence with a dose of 10 mg nocte for the first week. It is necessary to maintain the 
tricyclic for at least 12-18 months before considering the discontinuation of the drug (78). 
TCAs provide background analgesia by preventing the reuptake of serotonin (and / or 
noradrenaline) at central sites. Serotonin and noradrenaline have analgetic or algogenic 
properties that are site specific; increased concentrations of serotonin and noradrenaline at 
central receptor sites provide analgesia, while increased concentrations at peripheral sites 
cause pain. Common side effects of TCAs include anticholinergic effects such as 
xerostomia, weight gain, and sedation. More serious side effects include postural 
hypotension and arrhythmia, and there is an overdose mortality rate of 11-15 times 
compared with anticonvulsants. The frequent side effect of sedation, however, may be 
beneficial as it assists the patient’s sleep pattern, which is often disturbed in chronic pain 
patients. TCAs are more acceptable for anxiolysis and night sedation than diazepam. The 
newer tetracyclic antidepressants are less toxic and have fewer side effects than the 
tricyclics, but do not appear to possess the analgetic properties of tricyclics.  
  59
Anticonvulsant drugs 
Anticonvulsant drugs are appropriate where the pain has sharp, shooting, paroxysmal 
qualities. They have a membrane stabilising effect, causing a general reduction in the 
excitability of neurons. Anticonvulsants to be considered include carbamazepine and 
sodium valproate. Carbamazepine can increase brain concentrations of serotonin and 
sodium valproate can increase concentrations of gamma-aminobutyric acid (GABA). The 
starting dose for carbamazepine is usually 100 mg tds (and 100 mg nocte for elderly 
patients) and is gradually increased until a therapeutic effect is achieved (or side effects 
occur). The effective dose may need to be as high as 400 mg tds, but at this dose side 
effects of sedation, ataxia and gastrointestinal upset are common. Regular blood counts are 
necessary due to the possibility of thrombocytopenia and bone marrow depression. 
Sodium valproate appears to be less toxic than carbamazepine, and is generally better 
tolerated. Gastrointestinal disturbance and sedation are common side effects. In addition, 
disturbances of hepatic function may occur with sodium valproate and routine measurement 
of liver enzymes is necessary. Phenytoin is a second- or third-line anticonvulsant as it has a 
narrow therapeutic range and a potential side effect is marked gingival hyperplasia. 
Gabapentin is a recently introduced anticonvulsant that has an improved therapeutic effect 
to side effect ratio. However, its relatively high cost (~ $250 per monthly script) currently 
restricts its more widespread use as the drug is not currently listed with the Australian 
Pharmaceutical Benefit Scheme for pain management, in spite of published reports 
establishing its efficacy for managing neuropathic pain (79, 80, 81). 
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Other oral systemic antineuropathic drugs 
Clonazepam is a benzodiazepine primarily used for treating epilepsy, and accordingly its 
anticonvulsant properties render it useful for sharp, lancinating pain. Mexiletine, a cardiac 
antiarrhythmic agent and lignocaine analogue, is useful and should be considered if the 
patient has had a positive response to a lignocaine infusion. Drugs including long acting 
opioids, that contain morphine as the active agent, should be used with caution and as a 
last resort. There is the possibility that over a period of time (after 2 years) opioids may 
increase the pain (seen as a resistance or tolerance) through central sensitisation, by an 
increase in central concentrations of protein kinase C (26). Patients with a history of 
chemical dependency should be excluded and there should be one prescriber and one 
dispenser. Short acting opioid analgetics, such as codeine and pethidine, often used for 
acute pain, are contraindicated in the long term management of neuropathic orofacial pain. 
NSAIDS, such as ibuprofen, have been shown to be effective for diabetic neuropathy but 
adverse effects, including gastrointestinal ulceration, preclude their long term use. Several 
other drugs and routes of administration, for example, intravenous ketamine and topical 
aspirin, are effective for neuropathic pain, but may be limited in their application for 
intraoral use due to side effects (e.g. the ‘aspirin burn’ when aspirin is left to dissolve in the 
buccal sulcus). A systematic review of drug trials for peripheral neuropathic pain has been 
recently published (82). 
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Topical agents 
Capsaicin (8-methyl-N-vanillyl-6-noneamide, cayenne pepper) is derived from capsicum 
fruit and its prime role for medical applications has been for the treatment of dermal lesions 
of postherpetic neuralgia (83). The substance has both algesic and analgetic properties, 
and depending on the concentration used, capsaicin can selectively activate, deactivate and 
even destroy small diameter afferents, but leaves larger diameter afferents and the CNS 
intact. It can deplete several algogenic peptides, including substance P, calcitonin gene-
related peptide, somatostatin and vasoactive intestinal peptide. Capsaicin is a topical, first-
line antineuropathic agent with established efficacy in treating neuropathic oral pain. One 
report assessed the topical application of capsaicin to 30 patients with neuropathic 
orofacial pain (8). In this study patients were instructed to apply the agent (0.025% 
capsaicin) for three minutes, twice daily, to the area of intraoral pain. To limit any stinging / 
burning sensation from applying capsaicin, patients prerinsed their mouths with a topical 
anaesthetic mouthwash for three minutes. Results of the capsaicin trial showed a significant 
pain reduction in the test group. Nineteen patients reported a significant reduction in pain 
that ranged from 10-100% (mean = 58±25 SD). At long term review (mean = 13 
months), there was no significant change in pain compared with results from the four week 
capsaicin trial; the positive responders had maintained a mean pain reduction of 50% (±34 
SD). Other topical preparations specific for dermal use in conditions such as postherpetic 
neuralgia include powdered aspirin in chloroform or ethyl ether, and indomethacin, which 
inhibits prostaglandin synthesis (84).  
2. Sympathetic blockade  
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There is limited information on the management of the SMP component of neuropathic 
orofacial pain. The recommended technique is a series of stellate blocks conducted by an 
anaesthetist. The concept is to repetitively break the pain cycle administering one block per 
week for four to six consecutive weeks using a long acting local anaesthetic such as 
bupivacaine. In an uncontrolled study involving five subjects, researchers administered 
repeat stellate blocks using variable protocols with all subjects reporting pain reduction at 
follow up (ten months – three years) (9). A possible alternative treatment is clonidine, an 
a2-adrenoceptor agonist that reduces sympathetic activity in the brainstem. Peripherally, 
clonidine acts at prejunctional a2-receptors to reduce noradrenaline release. Transdermal 
applications of clonidine reduce pain and hyperalgesia at the local site of application. An 
uncontrolled study assessed its efficacy for treating neuropathic orofacial pain. Clonidine 
was applied, 0.2 mg/g in a cream base, four times a day to the site of pain; results showed 
that 6/12 patients had a positive response but with a wide variability in reducing pain 
intensity, ranging from 10-90% (85). 
 
3. Temporomandibular disorder 
Approximately two thirds of patients with neuropathic orofacial pain subsequently develop 
a TMD (8). Treatment of TMD, without attending to the causal neuropathic pain factor, 
however, does little in reducing the overall pain problem. Pain arising from TMD is 
predominantly due to bruxism. This can result in myofascial pain from masticatory muscle 
spasm (jaw clenching) and sensitisation of C-fibres in the periodontal, periapical and pulpal 
tissues of the oral cavity. Accordingly, there is a range of options available to help manage 
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the condition including drugs, physiotherapy, and occlusal splints and other dental 
appliances. Drugs such as NSAIDS are appropriate for acute muscle spasm but should be 
used with caution; ideally NSAIDS should only be considered as a rescue medication in 
the chronic pain patient. 
 
Physiotherapy encompasses a broad range of treatments that is initiated by the 
physiotherapist, and subsequently maintained by the patient. Initial treatment can include 
ultrasound, short wave diathermy, and laser to the affected musculature. Further 
professional instruction should be given to the patient regarding jaw (and neck) extension 
exercises and these should be rigorously pursued on a home basis by the patient. Other 
simple home physiotherapy measures include the frequent application of heat packs. 
 
Specific dental treatment can use occlusal splints to break the muscle spasm and to prevent 
tooth attrition. It should be noted, however, that while there is extensive documentation on 
splint design and clinical usage, well designed controlled studies indicate a significant 
placebo response from splints (86). On the other hand, where there is clear evidence of 
occlusal problems as a result of the extraction of teeth carried out in an attempt to cure the 
pain, then an occlusal splint as a prelude to occlusal rehabilitation with a permanent 
prosthetic appliance is warranted.  
 
4. Psychological factors  
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The MPQ, in addition to providing information on sensory qualities of pain and subsequent 
appropriate choices for drug trials, offers pertinent information on aspects of psychological 
distress. For example, patients with trigeminal neuralgia often list sensory descriptors such 
as shooting, stabbing and cutting that indicates trials of anticonvulsant drugs are indicated, 
yet they tend to be economical in the use of descriptive words. However, chronic pain 
patients with a nociceptive basis to their pain problem and significant psychological distress 
are likely to return a longer list of descriptors and include words such as sickening, 
terrifying and cruel as qualities of their pain. Specialist psychological or psychiatric 
assessment is a requisite for patients listing multiple, affective pain word descriptors (87). 
 
For any patient with a chronic pain condition, the potential role of psychological factors in 
magnifying, minimising, or maintaining pain should not be underestimated. The use of 
written information in the form of a pain questionnaire can offer valuable information on the 
magnification of pain and unrealistic expectations of treatments (Figure 9). One study 
demonstrated that the amount of treatment that patients with back pain received bore more 
relationship to the distress and illness behaviour they exhibited, than to the physical disease 
(88). It is imperative that any chronic pain patient undergoes assessment by a clinical 
psychologist and / or psychiatrist with expertise in pain medicine. Pain is a subjective 
experience and is determined by psychological and environmental factors, in addition to the  
underlying  pathology. There  can be  wide  individual variation of  
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Figure 9. Psychological variables in chronic pain. A 38-year-old female with neuropathic 
pain of two years duration, magnifying her pain report and having unrealistic expectations 
of treatment. (a) There was a pain score of “10 million”, yet she was “certain” that the pain 
would be cured, and only a “100% reduction in pain was acceptable”. (b) There was a 
history of past physical abuse including torture in her country of birth and she described her 
pain as having “terrifying” and “torturing” qualities on the McGill Pain Questionnaire.  
 
(a) 
 
 
(b) 
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how a patient demonstrates his / her pain to their practitioner(s) (Figure 10). Pain may 
often lead to anxiety and tension that, in turn, may increase the pain. Furthermore, pain 
intensity ratings are doubled when stress is present (89), and other studies have previously 
shown a strong and positive correlation between pain severity and impairment of activities 
(90, 91). 
 
The chronic pain patient may be unable to cope with his / her situation, which can lead to 
loss of self confidence, avoidance of others, and feelings of hopelessness and helplessness. 
They may blame the clinician for failing to solve the problem and there can be outright 
hostility and anger, and perhaps litigation, directed towards practitioners who they perceive 
have made the condition worse through inappropriate treatment. This can lead to an 
inability to communicate effectively and constructively with practitioners. The clinical 
psychologist (and psychiatrist to identify organic disorders) serves a key role to enable the 
patient to reach a better understanding of  important  pain  management  issues such  as  
achieving a  realistic outcome, self responsibility for long term management, and 
acceptance of the clinician’s advice. Operant conditioning may exist between patient and 
doctor, for example the continual advice on pain relief or cure for intractable chronic pain, 
and secondary emotional gain may be present between patient and caregiver, with the 
continuance of pain to obtain support, sympathy and control (22). 
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Figure 10. Expression of facial pain and psychological distress. A 55-year-old female with 
neuropathic orofacial pain and secondary temporomandibualr disorder displaying her pain. 
She had suffered a facial assault by a close female relative over a family dispute. She was 
in great distress and there were significant psychological factors involved. 
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It is important to obtain positive evidence of psychological factors playing a causal role as 
well; diagnosis by exclusion is clearly to be avoided. If a patient appears to have no clear 
pathological basis to his / her pain, referral for psychological assessment must be handled 
carefully lest the patient perceives it as being told “the pain is in your head”, which is likely 
to result in rejection of advice. If psychological assessment is sought, it should only be 
performed by a psychiatrist or clinical psychologist who has expertise in the field of pain, 
and the reason for the referral should be fully explained to the patient. For example, it 
should be explained that such pain problems are complex, and are associated with suffering 
and distress. In order to get a complete understanding of this pain, it is thus highly advisable 
to have input from appropriately experienced clinicians to assess the psychological aspects 
of pain, and the problems it causes. Most importantly, the medical / dental practitioner and 
the patient must have a common understanding prior to psychological / psychiatric 
assessments that the patient “is not crazy” or “imagining the pain”. For the referring 
clinician, it should be noted it is possible that previously undetected pathophysiology may 
exist in conditions that can be difficult to diagnose such as neuropathic orofacial pain. 
Psychological strategies employed in pain management include cognitive behavioural 
therapy (modifying attitudes, beliefs and expectations), relaxation and biofeedback, and 
hypnosis.  
 
In summary, pain management programmes are recommended for those who are not 
coping with their pain with the aims to (i) increase self perceived control over pain, (ii) 
increase self perceived independence, (iii) increase levels of physical and social activity, 
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and (iv) reduce levels of emotional distress. On a pharmacological basis there is the need 
to rationalise (discontinue or reduce) the use of inappropriate medication.  
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CHAPTER 5 
 
Case Studies 
 
Case Study 1  
History, presentation and investigations 
A 43-year-old female, married with three children, described a ten year pain history. She 
lived with her family, worked as a travel consultant, and was a social drinker (1 alcoholic 
drink per day). She claimed there was constant pain in tooth 16 (maxillary right first molar 
- International Dental Notation Classification) in the period from 1988-91. The tooth was 
sensitive to pressure, and hot and cold stimuli. Her general dental practitioner treated the 
tooth with root canal therapy (RCT) in 1991, and a crown was subsequently placed. The 
pain persisted and there was an increase in sensitivity to percussion and cold stimuli. The 
dentist carried out a further RCT but there was no change in her symptomatology. She was 
then referred to an endodontist. The endodontist was unable to negotiate intracanal ledges 
and thus periapical surgery was performed in December, 1997. Healing was uneventful, 
however the pain continued. The adjacent tooth (15) then became sensitive to cold stimuli. 
An endodontic colleague who believed that the area of pain (15-16) was not associated 
with 16 sought a further opinion. An opinion from a prosthodontist followed and an 
occlusal splint was issued. The splint therapy was only “partially beneficial” (patient’s 
words) and she discontinued wearing the appliance. Periapical surgery was again 
performed on 16 in June, 1998. No pathology was detected at the time of surgery, healing 
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was again uneventful, but the pain persisted. In August, 1998, 15 was still sensitive to cold 
stimuli, the pulp was extirpated and a coticosteroid  / antibiotic paste (Ledermix, Lederle 
Laboratories, Wolfrathausen, Germany) placed. There was still no change in 
symptomatology and the patient was referred by the endodontist to the PMRC for 
multidisciplinary pain assessment.  
 
Other investigations performed during the course of endodontic treatment included CT 
scan (no pathology detected), general medical assessments and an opinion from an ear, 
nose and throat surgeon. The patient’s previous dental history included the removal of 
supernumerary teeth at seven years of age, and the surgical removal of impacted third 
molar teeth and other supernumerary teeth at 14 years of age. Her medical history was 
unremarkable apart from an allergy to penicillin based drugs. 
 
Pain characteristics and psychological factors 
The pain was situated in the region of the 16 tooth and the adjacent buccal gingivae and 
mucosa. The pain had also spread extraorally to affect the facial tissues around the right 
temporomandibular joint. The temporal quality of pain as reported by the patient was 
constant, but there were occasional short periods without pain. Pain intensity as measured 
by the numerical rating scale showed the pain to have a usual level of 5/10, that varied from 
0-9 during the day, often no pain on awakening, but 7-9/10 by the afternoon (0 = no pain, 
10 = worst pain imaginable). On the verbal descriptor scale, the pain was medium to 
severe. Modalities that worsened the pain included local pressure on the gingivae, tension, 
  72
tiredness, eating, and dental procedures. Modalities that ameliorated the pain included 
sleep, analgetics and “keeping my mind off the pain”. MPQ word descriptors listed by the 
patient included pounding, flashing, gnawing, hot, aching and tender sensory qualities, and 
exhausting, troublesome, penetrating and nagging affective / miscellaneous qualities. Clinical 
examination showed a TMD was present and had developed subsequent to the 
neuropathic oral pain. The TMD signs and symptoms included temporomandibular joint 
pain, headaches, blocked ear, bruxism, sinusitis-like symptoms, occasional facial 
numbness, and episodes of swelling and heat in the face and in the buccal vestibule of the 
lip.  
 
There was no obvious clinical depression as determined by psychological assessment and 
completion of several psychological questionnaires including the MOS Health Survey (92), 
the Beck Depression Inventory (93), and the Pain Self-Efficacy Questionnaire (94). The 
patient had indicated at her first pain centre consultation that even with medical treatment, 
she realistically expected the pain “will not change”. Despite her lack of confidence in the 
prognosis of the condition, she was interested to find out what was the diagnosis of the 
condition and the cause of her pain. 
 
Diagnosis and management 
The medication at the time of her referral included prescription and ‘over the counter’ 
drugs: two Panadol tabs (paracetamol 500 mg tabs) prn, two Nurofen tabs (ibuprofen 200 
mg tabs) prn, and Rohypnol ½ tab (flunitrazepam 2 mg tabs) prn. The patient was 
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diagnosed with neuropathic orofacial pain with a secondary TMD. A six week trial of 
Zostrix (0.025% capsaicin) applied topically to the site of intraoral pain was commenced, 
concurrent with the introduction of a TCA. The TCA was amitriptyline; this was increased 
from 25 mg nocte to 75 mg nocte over three weeks and then maintained at that dosage. 
At a review at two months following the combined treatment, the patient claimed a 90% 
reduction in pain. She currently uses the capsaicin on an occasional basis when there is 
breakthrough pain. This reduces the pain back to basal levels in two to three days. Her 
medical doctor, who currently manages the patient (amitriptyline prescriptions), reported 
slightly raised liver enzymes (a rare side effect of amitriptyline) that is being monitored. 
 
Case Study 2  
History, presentation and investigations 
A 23-year-old healthy male, a final year medical student, described a four year history of 
chronic pain situated in the left jaw and face. The original cause of the pain was thought to 
be chronic infection of the 38 (mandibular left third molar). An oral surgeon extracted the 
tooth but pain and infection persisted and another dentist extracted the adjacent second 
molar several months later. There were no further episodes of infection but the pain was 
still present and then spread to the maxillary left molars. 
 
There had been no diagnosis that could explain the chronic pain complaint from the 
investigations carried out over the four year history. During the course of the pain, he had 
seen three oral surgeons and one dentist who conducted clinical examinations, and 
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periapical and orthopantomogram (OPG) radiographs. Two ear, nose and throat surgeons, 
two neurologists, an allergy specialist and four general medical practitioners also 
investigated him. In addition to routine clinical assessments by the medical specialists, 
investigations included blood tests, and CT and MRI scans of the brain.  
 
Pain characteristics and psychological factors 
The pain was centred in the left mandible 70% of the time, and 30% of the time it was 
centred in the left maxilla. The pain intensity varied from 1-5/10 with severe pain episodes 
rated 8/10. There were periods of being pain free and of severe pain, both periods lasting 
days or weeks. Pain qualities ticked on the MPQ were: throbbing, sharp, tugging, tingling, 
aching, taut, tiring, punishing, intense, spreading, tight, cold and dreadful.  
 
Psychologically, the patient believed that underlying, “perhaps sinister” pathology was 
initially responsible for the pain. Later, unremarkable findings from investigations then led 
him to conclude it was not life-threatening pathology but the pain had a “marked effect”. 
He felt “frustrated, despondent and anger towards unsympathetic doctors, no suicidal 
thoughts but periods of mild depression”. He questioned himself “can your mind create this 
pain from psychological and social factors?; I am doubtful of my normal senses - am I 
hallucinating regarding this pain?” He intentionally hid his condition from medical colleagues 
as he believed there was a stigma associated with chronic pain - a belief he attributed to 
the attitudes of his medical teachers (consultants and registrars) that these patients were 
“constantly complaining, narcotic dependent, and had personalities that were warped by 
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the pain problem”. Study and university results were affected and he believed this would 
result in restricted employment opportunities. He relied on his parents for ongoing support 
and his social life was greatly affected with an 80% decline in pursuing hobbies and social 
activities. 
 
Diagnosis and management  
The patient self referred himself to a specialist oral surgical practice in a regional city visited 
on a part time basis by the author. He had previously self prescribed Tofranil (imipramine 
10 mg tabs) and discontinued it after 1-2 days due to side effects (“it was awful and I felt 
like a zombie even on 10 mg”). The patient was diagnosed with neuropathic orofacial pain 
with a secondary TMD but he declined referral for multidisciplinary pain assessment at the 
author’s institution. There was marked spasm in the left masseter muscle. He undertook a 
six week trial of Zostrix (0.025% capsaicin) but it was not beneficial. The patient currently 
self medicates and uses rescue doses once / twice a month of Imigram (sumatriptan 50 mg 
tabs) and 4-6 tabs of Panadeine Forte (paracetamol 500 mg, codeine 30 mg per tab); his 
current use of medication for chronic pain is not recommended. In addition, he uses 
distraction strategies (work, study, television) and relaxation techniques to manage the 
pain.  
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Case study 3  
A 55-year-old Caucasian male underwent cancer surgery for carcinoma of the soft palate 
in 1995. He had a background medical condition of Charcot-Marie-Tooth disease. For 
the surgery, he had his mandible split for access. Three months after the surgery he 
complained of pain at the intraoral site of the incision passing over the mandibular alveolar 
crest (Figure 11). He described the pain as “very painful” and scored 6/10 on the NRS. 
MPQ word descriptors ascribed to the pain included crushing, pulling, tiring, annoying, 
radiating and numb qualities. At the time of his first pain management consultation he 
reported poor pain relief using a preparation containing 30 mg codeine and 300 mg 
paracetamol per tablet, with an intake of 8 tablets per day for 3 years. He had previously 
tried mexiletine (200 mg), amitriptyline (50 mg), and carbamazepine (200 mg) daily for 
pain relief but had discontinued these medications, as they were ineffective. He was 
engaged in full time employment, and was in a stable, happy marriage with two children. 
His responses to psychological questionnaires revealed he had a positive attitude towards 
managing chronic pain. However, based on his previous three years of failed medical 
treatments he believed that his pain condition would get worse.     
 
The patient underwent a trial of topical capsaicin that was applied to the site of the incision. 
For the trial he applied a topical anaesthetic mouthrinse to the mucosa for three minutes 
then followed by a three minute application of 0.025% capsaicin cream (Zostrix). This  
was  carried out  morning and  evening for  six weeks. At  his  review 
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Figure 11. Case study 3: (a) photograph of facial profile and external scars four years after 
cancer resection, (b) the painful site was the incision line over the mandibular alveolar crest 
(indicated by X) and radiating along the mandible and into the right side of the neck (N.B. 
patient error on shading left side of neck). 
 
 
     (a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     (b) 
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appointment at eight weeks he reported “very good pain relief” and had ceased his codeine 
/ paracetamol intake entirely.  
  
Several features of this case are worthy of comment. The head and neck surgeon who had 
carried out the operation was pleased with the surgical result and the patient was being 
reviewed every six months for possible recurrence. The surgeon initially thought that the 
pain may have been due to recurrence but there were no other features suggestive of 
recurrence and he was unable to explain to the patient the nature or source of his pain. The 
surgeon declined responsibility for managing the persistent pain and referred him to his 
local doctor for pain relief. His doctor had considered the pain to be neuropathic in origin 
and conducted trials of mexiletine, amitriptyline, and carbamazepine. However, while the 
drug selections were appropriate for this patient, the dosage of all three drugs was in the 
subtherapeutic range. It is likely that the patient would have gained benefit at dosages of 
mexiletine 600 mg (200 mg tds), amitriptyline 75 mg (nocte), and carbamazepine 600 mg 
(200 mg tds). The long term use of codeine was ill-advised and he continued its use for 
three years despite the drug providing only marginal benefit. It is likely that had the surgeon 
been knowledgable about neuropathic pain, the early intervention of capsaicin would have 
prevented three years of unnecessary pain and suffering.   
 
Psychological assessment 
The patient was well motivated, as he did not want the pain to disrupt his marriage or 
work. He had realistic expectations of treatment - a 50% reduction in pain as being 
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acceptable to live with. He was satisfied with obtaining good pain relief and was not 
seeking complete pain relief. The patient had not demanded additional medication for 
further pain relief as he recognised that an increased drug dose may initiate drug side 
effects, thus potentially hampering his work performance and enjoyment of family life. By 
having a positive, hopeful attitude and agreeing to take the responsibility for his own 
improvement, he has complied with treatment guidelines, applying the capsaicin that is 
currently used sparingly. He continues to report excellent long term pain relief. 
 
Case study 4  
A 65-year-old Caucasian male, who in June, 1997 worked as a truck repairer, suffered 
severe maxillofacial trauma as a result of a crush injury at work. He incurred a Le Fort II 
fracture of the maxilla with significant displacement of the walls of the antrum and orbital 
floor (Figure 12). He subsequently underwent internal fixation with plates. He was referred 
to the PMRC for multidisciplinary assessments. The pain was constant and rated 6/10 on 
the NRS. MPQ word descriptors ascribed to the pain included throbbing, shooting, 
stabbing, sharp, aching and splitting sensory qualities, and exhausting, punishing, annoying, 
intense, piercing, tearing and torturing affective and evaluative qualities. He was married 
and lived with his wife. At the time of his referral he was taking 2 g paracetamol daily. He 
had previously trialed carbamazepine but it was discontinued after only two weeks due to 
excessive drowsiness. He reported a poor sleep pattern of only two hours sleep each 
night.  
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Figure 12. Case study 4: (a) facial photograph of patient two years after crush injury to the 
right side of the face, (b) CT section of facial fractures, (c) orthopantomogram of maxilla 
following open reduction and internal fixation of fractures, (d) pain map of multiple sites of 
pain showing neuropathic pain in the right maxilla and preexisting cervicogenic pain. 
 
 
     (a) 
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The patient was trialed on gabapentin with an escalating dose up to 900 mg daily over one 
week. At his review appointment at two months he had achieved a 50% reduction in the 
neuropathic facial pain by maintaining this regimen. He reported a slight occasional itch as 
the only side effect. He was still complaining of aching pain in the occipital region that was 
attributed to coexisting C 4/5 degenerative changes involving the facet joints (Figure 
12(d)).    
   
Psychological assessment 
The patient was a self-made man. He had worked very hard over many years and had 
always been a hard-driving, rather perfectionistic, person. At the time of his injury, he 
owned and managed his business and was financially very comfortable. The injury, 
hospitalisation and continuing pain problem interfered with his business. Yet he could not 
bring himself to employ a manager whom he could trust to oversee the business. As a 
result, work-related stress continued to interact with pain to produce an angry and 
depressed man. 
 
The patient sought 100% remission of facial and neck pain. He wanted his pre-injury face 
to be returned to him and would not be satisfied with anything less. He resisted the notion 
that this was an unrealistic expectation. As a result, despite his reports of a 50% pain 
reduction on gabapentin suggesting an excellent early result, the patient remained 
disappointed and distress levels remained high. 
 
  83
The results of the early gabapentin trial give rise to optimism that the neuropathic pain 
problem can be impacted by appropriate medication over a period of time. At the same 
time, psychological rigidity of attitude and expectations, high stress and sympathetic 
arousal, depression and an unwillingness to adapt to less favourable physical conditions 
threaten to undermine the pharmacological regimen. 
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 CHAPTER 6 
 
Future Directions in Neuropathic Pain Research: a Preliminary 
Study Evaluating an Application of High-Performance Liquid 
Chromatography-Mass Spectrometry 
 
Introduction 
As described previously in Chapter 3, there is a vast and diverse array of substances 
involved in the progression from acute to chronic pain. These substances involve protons 
and reactive oxygen species along with other recently identified substances such as 
excitatory amino acids, peptides, and hormones. A greater understanding of the various 
modulating effects of these native substances on each other could lead to the development 
of improved pharmacotherapeutic interventions aimed at preventing or restricting the 
development of a chronic pain state. Determination of any role(s) of the various peptides 
involved in mechanisms of causality of chronic pain involves a number of fundamental steps: 
(i) identification and confirmation of the substances involved, (ii) determination of 
concentrations of each substance, and (iii) identification of the biological effect(s) of each 
substance, and at what stage of the pain pathway (acute to chronic pain) the substance is 
involved. A barrier preventing a greater understanding of this complex process is the lack 
of availability of multiple specific assay techniques to measure the concentration of each 
analyte (amino acid / peptide) identified. Whereas immunoassay techniques have been 
employed in this role, usually affording measurement of the concentration of the substance 
in the femtomolar range, their disadvantages include a possible lack of specificity, lengthy 
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laboratory steps such as incubation times, and the determination of only one analyte per 
sample. This can subsequently limit the amount of information that can be potentially 
acquired from each sample, for example, research investigating multiple peptides and their 
active degradation products.  
 
A technique that would allow the identification, confirmation and measurement of multiple 
analytes from a single prepared sample in a relatively short time would be of considerable 
benefit in extending the knowledge base of peptides involved in pain mechanisms. 
Moreover, a technique that could assay the various drugs used for treating neuropathic 
pain could secure further knowledge of their respective pharmacokinetic profiles leading to 
improved titration and dosage scheduling. One potentially useful technique for assaying 
drugs and biological substances of interest is high-performance liquid chromatography 
coupled to mass spectrometry (LC-MS). 
 
This chapter describes a preliminary study evaluating LC-MS as a possible technique to 
overcome some of the limitations of immunoassay. The purpose of this study was to assess 
the utility of LC-MS by analysing mass spectra and retention times of several analytes of 
interest in a single sample. In this preliminary investigation the analytes used were drug and 
peptide standards. The peptides selected are documented to play a role in pain 
mechanisms, and drugs selected that are used in the diagnosis and management of 
neuropathic pain (lignocaine, capsaicin, carbamazepine, trimipramine) or nociceptive pain 
(morphine, fentanyl).  
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Reagents, drug and peptide standards  
Formic acid (AJAX Laboratory Chemicals, Sydney, NSW, Australia) and acetonitrile 
(EM Science, Gibbstown, NJ, USA) were HPLC grade. The nebulising and desolvation 
gas for the mass spectrometer electrospray interface was nitrogen that was generated from 
a Pilot nitrogen generator (Carat P.L., Silverwater, NSW, Australia). Water was obtained 
from a Milli-Q water purification system (Millipore, Bedford, MA, USA). Solvents were 
filtered through 0.2 mm membrane filters (Millipore, Ireland) for use in liquid 
chromatography and electrospray analysis. Peptide standards were purchased from 
Auspep (Parkville, VIC, Australia) and Sigma-Aldrich (St. Louis, MO, USA). Drug 
standards were obtained from the hospital pharmacy (Royal North Shore Hospital, NSW, 
Australia). The substances tested are given in Table 2. 
 
As the aim was to identify the retention times and m/z of the respective standards, and no 
subsequent biological samples were to be assayed, repeat injections of the mixture were 
not underaken to establish a validation curve at this stage of method development.  
 
Instrumentation and chromatographic methods 
For acquiring the mass spectra of the standards, separate direct injections into the mass 
spectrometer were made of each standard (10 mL of 5 mg/mL of each standard) using a 
10 mL injection loop. The infusion flow rate was 10 mL/min provided by a Harvard 
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Apparatus syringe driver (Natick, MA, USA). Standards were dissolved in 50% 
acetonitrile, 0.5% formic acid for injection into the mass spectrometer. 
 
High-performance liquid chromatography (HPLC) was carried out with a SMART System  
(Pharmacia  Biotech)  that  was  comprised  of  two  10 mL  syringe  pumps. Gradient 
chromatography was employed. Solvent A was 0.5% formic acid and solvent B was 90% 
acetonitrile, 0.5% formic acid; B increased 0% to 100% over 45 minutes. The flow rate 
was 200 mL/min and an 8:1 splitter was used for introduction of the effluent to the 
electrospray source. The HPLC column was a 5 mm particle size, 300Å pore size, 250 × 
1 mm internal diameter, C8 Primesphere stainless steel column (Lot no. 136484) 
(Phenomenex, Torrance, CA, USA), with a 30 × 1 mm internal diameter Primesphere 
guard column (Lot no. 137100G) (Phenomenex, Torrance, CA, USA).  
 
The mass spectrometer was a single quadrupole Micromass Platform II (Manchester, UK) 
equipped with an electrospray interface and was coupled to the HPLC or syringe driver. 
The acquisition parameters were as follows; ionisation mode ES+, capillary voltage 3.5 
kV, HV lens 0.5 kV, skimmer offset 5 V, source temperature 120 °C, ion energy 10 V, 
LM resolution 15.0, HM resolution 15.0, multiplier 650 V. The flow rate of nitrogen for 
nebulisation was 10 L/h, and for desolvation was 300 L/h. Mass spectra were collected in 
continuum mode over a mass to charge (m/z) ratio  range of  100 to  2000.  Acquisition  of  
data  was  performed with a scan every  
  88
eight seconds and an interscan interval of 0.1 seconds using MassLynx NT (Version 3.0) 
software or using the MaxEnt program within MassLynx.  
 
Results 
The 27 standards (Table 2) all showed characteristic mass spectra from separate direct 
infusions into the mass spectrometer e.g. Figure 13. All drugs showed the base peak 
(100% relative abundance) to have a m/z of [M + 1H]1+. Some drugs displayed additional 
peaks representative of dimerisation and adduct formation (e.g. carbamazepine with m/z at 
237 [M + 1H]1+, dimerisation at 473 [M + 2H]2+, Na+ adducts at m/z 259 and 495) 
(Figure 13 (b)). The other 15 standards (11 peptides, prostaglandin E2, serotonin, 
histamine, and the enzyme inhibitor antipain) varied with a m/z ranging from [M + 1H]1+ to 
[M + 4H]4+ (b-endorphin (1-27)) (Figure 13 (c)) with many peptides showing several m/z 
peaks.   
 
On the LC-MS, all 27 analytes could be resolved by the mass spectrometer from a 
mixture injected into the LC-MS and standards eluted within the 45 minute LC-MS run 
time (Table 2, Figure 14). Analytes with similar m/z were resolved by chromatography as 
seen by different retention times (Figure 15). Several analytes had identical retention times 
(fentanyl, midazolam, kallidin and angiotensin II at 22.92 minutes; g-endorphin and 
substance P at 26.62 minutes) that could be quantitated by their respective m/z (Figure 
16). 
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Table 2 
Analyte m/z and retention time from direct MS infusions and LC-MS 
 
 
Analyte MW 
(Daltons) 
m/z Retention time 
(Minutes) 
Drug    
Prilocaine 220.3 221 5.41 
Clonidine 230.1 230 6.59 
Lignocaine 234.3 236 6.76 
Carbamazepine 236.26 237 14.84 
Mepivacaine 246.34 247 7.6 
Ketoprofen 254.3 255 23.42 
Diazepam 284.76 285 22.25 
Morphine 285.33 289 36.72 
Trimipramine 294.42 295 23.93 
Capsaicin 305.4 306 26.29 
Midazolam 325.77 326 22.92 
Fentanyl 336.46 342 22.92 
    
Peptide /other    
Histamine 111.2 112 4.23 
Serotonin 176.2 177 4.23 
Prostaglandin E2 352.5 353 36.22 
Antipain 604.7 303 22.41 
Dermorphin 802.9 804 42.61 
Angiotensin II 1046.2 524 22.92 
Bradykinin 1060.2 531 33.86 
Arg-vasopressin 1084.2 543 21.91 
Neurokinin A 1133.3 567 23.26 
Kallidin 1188.4 397 22.92 
Substance P 1347.6 675 26.62 
Somatostatin 1637.9 547 28.31 
a-endorphin 1746.0 874 23.93 
g-endorphin 1859.1 930 26.62 
b-endorphin (1-27) 3022.5 757 33.19 
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Figure 13. Mass spectral data of three standards (fentanyl, carbamazepine and b-
endorphin (1-27)) from separate direct infusions (10 mL of 5 mg/mL of each standard 
dissolved in 50% acetonitrile, 0.5% formic acid) into the mass spectrometer: (a) fentanyl 
with m/z 342 [M + 1H]
1+
, (b) carbamazepine with m/z 237 [M + 1H]
1+
, dimerisation at 
473 [M + 2H]
2+
, and Na
+
 adducts at m/z 259 and 495, (c) b-endorphin (1-27) with 
multiple m/z at 757 [M + 4H]
4+
 and 1009 [M + 3H]
3+
 that was deconvoluted to identify 
MW at 3022. 
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Figure 14. Mass spectrometer chromatogram from a single injection of a drug and peptide 
mix (10 mL of 5 mg/mL) into the LC-MS. Chromatographic conditions were: solvent A 
was 0.5% formic acid and solvent B was 90% acetonitrile, 0.5% formic acid; B increased 
0% to 100% over 45 minutes; flow rate 200 mL/min and an 8:1 splitter to the electrospray 
source. Several large peaks displayed in the chromatogram (e.g. at 4.07 min and 42.78 
min) are due to extraneous substances eluting from the chromatographic column as a result 
of the introduction of acetonitrile (organic mobile phase component) in the gradient for the 
peak at 4.07 min and high concentration of acetonitrile for the 42.78 min peak.   
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Figure 15. Separation of two standards with similar m/z by retention time: (a) capsaicin 
(MW 305.4, m/z 306 [M + 1H]
1+
) showing a retention time of 26.29 minutes, (b) antipain 
(MW 604.7, m/z 303 [M + 2H]
2+
) showing a retention time of 22.41 minutes.  
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Figure 16. Confirmation of assignment and quantitation of four standards with identical 
retention times by different m/z (a) angiotensin II MW 1046.2, m/z 524 [M + 2H]
2+
, (b) 
kallidin MW 1188.4, m/z 397 [M + 2H]
2+
, (c) midazolam MW 325.77, m/z 326 [M + 
1H]
1+
, (d) fentanyl MW 336.46, m/z 342 [M + 1H]
1+
. 
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Discussion 
In this preliminary study, LC-MS showed itself to be a technique of tremendous utility by 
confirming the assignment of analyte identity to a broad range of drugs, endogenous 
substances, and one enzyme inhibitor. While gas chromatography-mass spectrometry 
(GC-MS) is a well proven instrument in drug analyses, the high temperatures needed in the 
GC makes it unsuitable for peptide analyses. Moreover, using a  simple LC-MS method, 
such  as  described  in this study, precludes the need for prior drug derivatisation, a 
necessity for some drugs employing GC-MS methodologies. The LC-MS was also useful 
in the separate confirmation of peptides with similar amino acid composition and sequence 
such as bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) and kallidin (Lys-Arg-Pro-
Pro-Gly-Phe-Ser-Pro-Phe-Arg). This was accomplished by both the LC (separate 
retention times of bradykinin and kallidin, 33.86 and 22.92 minutes, respectively) and the 
MS (different m/z of 531 and 397, respectively). Where multiple analytes exhibited the 
same retention time, entering the m/z of the particular analyte of interest gave a value for its 
relative abundance that can be used to determine the concentration of the analyte from a 
validation curve. In this respect, the coupling of the MS to the LC overcomes a major 
problem with using LC by itself, as co-eluting substances confound peak identity and 
integration when LC is used as a single technique. In addition, LC-MS has an advantage 
over immunoassay techniques due to the necessity of separate immunoassays for each 
peptide.  
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In summary, from this preliminary study using standards, LC-MS appears to have superior 
utility for multiple drug and peptide analysis when compared to other techniques (GC-MS, 
immunoassay, HPLC). This should enable further knowledge to be gained concerning the 
biological processes involved in neuropathic pain, and the pharmacodynamic and 
pharmacokinetic profiles of drugs used in the management of pain.  
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 CHAPTER 7 
A Summary of this Treatise 
 
The prevalence of neuropathic orofacial pain in society has yet to be accurately 
determined. The available reports are still limited to only a few retrospective studies. One 
report, nevertheless, stands out as being of great importance to the endodontic speciality 
group, with approximately 50% of patients in the study claiming pain as a result of 
endodontic treatment (9). However, it is impossible at this stage to state categorically that 
dental / endodontic treatment is a prime causal factor in the development of neuropathic 
pain. While various endodontic procedures employ mechanical and chemical trauma to 
pulpal and periodontal nociceptors, preexisting pulpitis may well be the trigger for 
neuropathic pain. For example, in the case of postherpetic neuralgia (shingles) of the skin, 
there is infection and inflammation without surgical intervention, yet the patient may develop 
a neuropathic pain. Formal, prospective epidemiological studies are warranted to establish 
the true prevalence of this condition associated with general dental treatment (restorations, 
scaling, extractions) and specifically, with endodontics. 
 
Chronic pain involves nociception and / or neuropathy, pain, suffering and pain behaviour. 
The pathophysiology of neuropathic pain is complex and involves deafferentation, nerve 
sprouting, neuroma formation, sympathetic efferent activity and centralisation. A great deal 
of current research is attempting to further define the mechanisms involved in this pain state. 
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Our current knowledge is based on animal research models and on investigations of well-
described human conditions such as postherpetic neuralgia and phantom limb pain. 
Published information on neuropathic pain states focus predominantly on anatomical 
locations arising from spinal cord dorsal root; there are scarce reports pertaining to the 
trigeminal sensory system. While the sensory nervous system displays identical 
physiological phenomena (nerve conduction) throughout the body, differences in the degree 
of sensory innervation, such as the highly innervated dental pulp and periodontal ligament, 
may play an important role in the acquisition of neuropathic orofacial pain.  
 
Conceptually, chronic pain involves nociception and / or neuropathy, pain, suffering and 
pain behaviour. Early referral (within six months) of a patient with chronic pain to a 
multidisciplinary pain clinic is recommended, where possible, for comprehensive pain 
assessments by a medical pain specialist, clinical psychologist, physiotherapist and others 
(dentist, social worker, etc). Neuropathic orofacial pain is a condition that can be difficult 
to diagnose and treat. However, there are simple, yet effective, diagnostic procedures such 
as the MPQ and the utilisation of sequential analgetic blockade that can assist the clinician 
in reaching a diagnosis. Psychological factors are important to identify as they can 
profoundly influence pain and pain behaviour. For example, a patient may expect 
substantial or unequivocal pain relief despite many years of suffering and failed treatments. 
Moreover, inordinate pressures can be placed on clinicians by patients with chronic pain 
who seek to commandeer the direction of pain treatments by suggesting further ablation 
(extraction / further endodontic treatment), or inappropriate drug treatment regimens such 
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as opioid drugs to manage the pain. It is recognised that chronic orofacial pain conditions 
have similar pain intensity ratings, as indicated by the PRI(T) of the MPQ, compared with 
back pain, cancer pain and phantom limb pain (33). However, this important point is 
probably overlooked by the general public because chronic orofacial pain does not raise 
the emotive responses inherent in cancer pain, nor the government / business concerns of 
lost work productivity and related economic considerations associated with back pain.  
 
Initial treatment and long term management must utilise a broad range of pharmacological 
and psychological measures individually tailored to the patient. The management of 
neuropathic pain arising from dental / maxillofacial injury, surgery and infection is similar to 
its management in other areas of the body. 
 
The use of capsaicin can serve dual purposes, as both a diagnostic agent and as a 
therapeutic agent. Principles for drug utilisation include the rationalisation of drug regimens 
to reduce and eliminate, where possible, opioids, sedatives and other drugs of 
dependence, and initiation of long term low dose TCAs, and adjunct medications such as 
anticonvulsants (carbamazepine, sodium valproate) and membrane stabilisers (mexiletine). 
Ancillary physical interventions for patients with TMD secondary to neuropathic orofacial 
pain include physiotherapy to jaw, neck and other musculature, and occlusal splints where 
bruxism is causing tooth attrition. 
Pain can be magnified or minimised by gender-related effects, socioeconomic variables, 
ethnocultural differences, pending litigation / compensation, secondary gain and drug abuse. 
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Thus, it is imperative that an assessment of the role of psychological and environmental 
factors be undertaken to subsequently instigate appropriate strategies. The practitioner 
should be aware of the following psychological variables in pain management: (i) unrealistic 
expectations, (ii) the motivation to improve, (iii) maintaining taught psychological coping 
skills and physical exercises, and (iv) accepting appropriate advice on the rationalisation of 
drugs. The institution of specialist psychological / psychiatric treatment should focus on the 
development of effective coping strategies (e.g. relaxation techniques, cognitive and 
behavioural strategies), problem solving skills, and dealing with unresolved issues in the 
patient’s life. The clinician needs to acknowledge and understand that, as a consequence of 
long term pain and suffering, there may be dire effects on the family and on the patient’s 
ability to have gainful employment.  
 
It is both prudent for the clinician and beneficial to the patient that sufficient and relevant 
advice be given to the patient, especially a satisfactory understanding of the 
pathophysiology of neuropathic pain. The patient may have a history of many years of 
suffering and failed treatments, including unnecessary repetitive surgery. Unfortunately, in 
many cases of chronic neuropathic orofacial pain, both the general dental / medical 
practitioner and the specialist are bewildered by this pain state through their lack of 
knowledge. Utilisation of multidisciplinary pain assessments leads to a correct diagnosis 
and may well save many patients from having a great deal of further unnecessary treatment, 
expense and suffering. In addition, this would allow the subsequent implementation of 
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interventions individually tailored to improve the chances of obtaining a successful outcome 
for the afflicted individual.  
 
A fundamental step to improve the management of patients with neuropathic pain lies in its 
early recognition by primary-care clinicians. Accordingly, the education of clinicians is an 
important area in the prevention and early treatment of patients with neuropathic pain. 
Formal training for professionals in multidisciplinary aspects of pain (neurobiology, 
pharmacology and psychology) is thus recommended. Applied knowledge should curtail 
the unfortunate, but frequent desire, for dental practitioners to carry out widespread pulp 
removal or the extraction of multiple teeth, in an attempt to ‘cure the pain’.  
 
Additionally, basic science researchers need to acquire a greater understanding of the 
complex biological processes involved in the pathophysiology of neuropathic pain. LC-MS 
is a powerful technique, and is potentially useful for identifying substances involved in these 
processes. Furthermore, from the described preliminary LC-MS study, the technique 
appears to have wide scope in measuring drugs of interest that are prescribed in the 
treatment of neuropathic pain. For future research, the next logical step is to evaluate its 
utility in the clinical setting by obtaining and assaying representative biological samples from 
patients with neuropathic pain. LC-MS would appear to offer the possibility of adding to 
the knowledge base on the neurobiology of pain, hence providing directions for the 
development of novel drugs. Furthermore, it is anticipated that the technique could identify 
and measure endogenous substances that may be released in psychological distress, 
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thereby suggesting a unique approach to quantifying distress and evaluating non-
pharmacological approaches to pain treatments such as psychological interventions.  
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